


*FORM PTO-1390 OFFICE (REV 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK		ATTORNEY'S DOCKET NUMBER  229752001300
<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. § 371</b>				U.S. APPLICATION NO. (If known, see 37 CFR 1.5)  <b>09/763957</b> to be assigned
INTERNATIONAL APPLICATION NO.  PCT/AU99/00705	INTERNATIONAL FILING DATE  31 August 1999	PRIORITY DATE CLAIMED  31 August 1998		
TITLE OF INVENTION  A NOVEL PLANT PROMOTER AND USES THEREFOR				
APPLICANT(S) FOR DO/EO/US  Jose Ramon BOTELLA MESA AND Christopher Ian CAZZONELLI				
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:				
<ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</li> <li>4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))             <ol style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li>6. <input type="checkbox"/> An English language translation of the International Application under PCT Article 19 (35 U.S.C. 371(c)(2)).             <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto.</li> <li>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</li> </ol> </li> <li>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).             <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> have been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input checked="" type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</li> <li>10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li> </ol>				
Items 11. to 16. below concern document(s) or information included:				
<ol style="list-style-type: none"> <li>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>13. <input type="checkbox"/> A <b>FIRST</b> preliminary amendment.</li> <li>14. <input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment.</li> <li>15. <input type="checkbox"/> A substitute specification.</li> <li>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</li> <li>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</li> <li>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</li> <li>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</li> <li>20. <input checked="" type="checkbox"/> Other items or information: Sequence Listing; Int'l Preliminary Examination; Not. of Receipt of Demand by Competent Int'l Preliminary Examining Authority; PCT Demand; Not. informing the Applicant of the Communication of the Int'l Appln. to the Designated Office; Int'l Search Report; PCT Request; and return receipt postcard.</li> </ol>				

**CERTIFICATE OF HAND DELIVERY**

I hereby certify that this correspondence is being hand filed with the United States Patent and Trademark Office in Washington, D.C. on February 28, 2001.

Marieta Luke

U.S. APPLICATION NO (if known, see 37 CFR 1.5) to be assigned <b>09/763957</b>	INTERNATIONAL APPLICATION NO PCT/AU99/00705	ATTORNEY'S DOCKET NUMBER 229752001300	
21. <input checked="" type="checkbox"/> The following fees are submitted:  <b>BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):</b>  Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... \$1,000.00  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... \$860.00  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$710.00  International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provision of PCT Article 33(1)-(4) ..... \$690.00  International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$100.00		<b>CALCULATIONS</b> PTO USE ONLY	
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>		\$860.00	
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$0	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	24 - 20 =	4	x \$18.00 \$72.00
Independent claims	5 - 3 =	2	x \$80.00 \$160.00
<b>MULTIPLE DEPENDENT CLAIM(S) (if applicable)</b>		+ \$270.00	\$270.00
<b>TOTAL OF ABOVE CALCULATIONS =</b>		\$1362.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by ½.		\$0	
		<b>SUBTOTAL =</b>	\$1362.00
Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		+ \$0	
		<b>TOTAL NATIONAL FEE =</b>	\$1362.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00 per property</b>		+ \$0	
		<b>TOTAL FEES ENCLOSED =</b>	\$1362.00
		<b>Amount to be refunded: charged:</b>	\$* \$*
a. <input checked="" type="checkbox"/> A check in the amount of \$1362.00 to cover the above fees is enclosed.			
b. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees that may be required, or credit any overpayment to <u>Deposit Account No. 03-1952</u> . A duplicate copy of this sheet is enclosed.			
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>			
SEND ALL CORRESPONDENCE TO:  Barry E. Bretschneider Morrison & Foerster LLP 2000 Pennsylvania Avenue, N.W. Washington, D.C. 20006-1888			
 SIGNATURE  Barry E. Bretschneider <u>Registration No. 28,055</u>			

A NOVEL PLANT PROMOTER AND USES THEREFOR**FIELD OF THE INVENTION**

5

The present invention relates generally to a novel plant promoter. More particularly, the present invention provides a plant promoter capable of induction by physical and/or environmental stimuli in cells in which the promoter is indigenous and, in the absence of any negative regulatory mechanism, is capable of 10 constitutive expression in cells in which the promoter is non-indigenous. The present invention is further directed to derivatives of the subject promoter including modular forms of the promoter which are, for example, inducible by different physical and environmental stimuli or which are constitutively expressed. The promoter of the present invention has a range of uses including directing 15 expression of genes conferring useful traits on plants.

**BACKGROUND OF THE INVENTION**

Bibliographic details of the publications referred to in this specification are collected 20 at the end of the description.

The subject specification contains nucleotide and amino acid sequence information prepared using the programme PatentIn Version 2.0, presented herein after the bibliography. Each nucleotide or amino acid sequence is identified in the sequence 25 listing by the numeric indicator <210> followed by the sequence identifier (e.g. <210>1, <210>2, etc). The length, type of sequence (DNA, protein (PRT), etc) and source organism for each nucleotide or amino acid sequence are indicated by information provided in the numeric indicator fields <211>, <212> and <213>, respectively. Nucleotide and amino acid sequences referred to in the specification 30 are defined by the information provided in numeric indicator field <400> followed by

the sequence identifier (eg. <400>1, <400>2, etc).

The designation of nucleotide residues referred to herein are those recommended by the IUPAC-IUB Biochemical Nomenclature Commission, wherein A represents 5 Adenine, C represents Cytosine, G represents Guanine, T represents thymine, Y represents a pyrimidine residue, R represents a purine residue, M represents Adenine or Cytosine, K represents Guanine or Thymine, S represents Guanine or Cytosine, W represents Adenine or Thymine, H represents a nucleotide other than Guanine, B represents a nucleotide other than Adenine, V represents a nucleotide 10 other than Thymine, D represents a nucleotide other than Cytosine and N represents any nucleotide residue.

The rapidly increasing sophistication of recombinant DNA technology is greatly facilitating research and development of a range of biotechnologically-related 15 industries. This is particularly the case in the horticultural, agricultural and plant industries. Substantial progress, for example, has been achieved in the genetic development of plant varieties exhibiting new or improved traits such as disease resistance, enhanced nutritional properties, greater tolerance to adverse environmental conditions and altered flower colour. However, progress in the 20 genetic manipulation of some plants has been hampered by the lack of sufficient effective promoters and/or the lack of promoters capable of being induced by commercially inexpensive and useful effector stimuli. Furthermore, more promoters are required to facilitate expression of multiple traits in a target species. There is a need, therefore, to identify new promoters and to identify and characterize effector 25 molecules and stimuli which are capable of inducing these promoters. There is also a need to identify promoters which are capable of directing constitutive expression.

Plants are subject to a variety of environmental and mechanical stimuli including stress. Although mechanical stress has been postulated to involve ethylene- 30 mediated meristem morphogenesis (Selker *et al*, 1992), little is known about how mechanical stress induces ethylene production or the signal transduction process

- 3 -

involved.

In work leading to the present invention, the inventors sought to identify and isolate promoters involved in mechanical stress-induced expression of genetic traits in 5 *Vigna radiata* (mung bean). Mung bean plants are a useful model for physical and chemical induction of phenotypic expression of genetic traits due to their morphology, rapid growth rate and the ability to obtain a large number of uniform plants and, therefore, sufficient amounts of tissues to conduct analyses.

- 10 In accordance with the present invention, the inventors have isolated a promoter capable of induction following physical stimulus in cells in which the promoter is indigenous, i.e. cells of mung bean plants. The promoter is also capable of being induced by a range of chemical and other environmental stimuli. However, in cells in which the promoter is non-indigenous, the promoter is constitutively expressed.
- 15 The promoter of the present invention is useful in the genetic manipulation of plants.

#### SUMMARY OF THE INVENTION

- 20 Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers.

25

The promoter of the present invention is referred to herein as "pGEL-1". The promoter was referred to as the "AIM-1 promoter" (or in some cases "A/M-1") in the priority application. Reference herein to "A/M-1" means the structural gene encoding ACC synthase from *Vigna radiata*.

30

One aspect of the present invention provides an isolated nucleic acid molecule

- 4 -

comprising a sequence of nucleotides or a complementary sequence of nucleotides defining a promoter or a derivative or homologue thereof wherein, in its native form, the promoter is inducible in response to physical stimulation.

5 Another aspect of the present invention is directed to an isolated nucleic acid molecule comprising a sequence of nucleotides or a complementary sequence of nucleotides defining a promoter or a derivative or homologue thereof, wherein said promoter, in its native form, directs expression of a gene associated with ethylene production and is inducible by physical stimulation.

10

Yet another aspect of the present invention relates to an isolated nucleic acid molecule comprising a sequence of nucleotides or a complementary sequence of nucleotides defining a promoter or a derivative or homologue thereof wherein said promoter, in its native form, directs expression of a gene encoding ACC synthase 15 and is inducible by physical stimulation.

Still another aspect of the present invention provides an isolated nucleic acid molecule comprising a sequence of nucleotides or a complementary sequence of nucleotides defining a promoter or a derivative or homologue thereof wherein said 20 promoter, in its native form, directs expression of a gene encoding ACC synthase or another gene associated with ethylene biosynthesis and is inducible by physical stimulation.

Still yet another aspect of the present invention is directed to an isolated nucleic acid molecule comprising a sequence of nucleotides or a complementary sequence of nucleotides defining a promoter or a derivative or homologue thereof wherein said promoter, in its native form, directs expression of a gene encoding an ACC synthase having an amino acid sequence substantially as set forth in <400>2 or an amino acid sequence having at least 60% similarity to <400>2.

30

A further aspect of the present invention relates to an isolated nucleic acid molecule

- 5 -

comprising a sequence of nucleotides or a complementary sequence of nucleotides defining a promoter or a derivative or homologue thereof wherein said promoter, in its native form, directs expression of a gene encoding ACC synthase and wherein said gene comprises a nucleotide sequence substantially as set forth in <400>1 or  
5 a sequence having at least 50% similarity thereto and/or a nucleotide sequence capable of hybridizing to <400>1 under low stringency conditions.

Still another aspect of the present invention is directed to an isolated nucleic acid molecule comprising a sequence of nucleotides or a complementary sequence of  
10 nucleotides defining a promoter or a derivative or homologue thereof wherein said promoter, in its native form, comprises a nucleotide sequence substantially as set forth in <400>3 or a nucleotide sequence having at least 25% similarity thereto or a nucleotide sequence capable of hybridizing to <400>3 under low stringency conditions.

15

Another aspect of the present invention provides a modular promoter, said modular promoter comprising at least one portion which is derived from a promoter which, in its native form, directs expression of a gene associated with ethylene biosynthesis and is inducible by physical stimulation.

20

Yet another aspect of the present invention is directed to a modular promoter, said modular promoter comprising at least one portion which is derived from a promoter which, in its native form, directs synthesis of an ACC synthase having an amino acid sequence substantially as set forth in <400>2 or an amino acid sequence  
25 having at least 60% similarity thereto.

Still yet another aspect of the present invention is directed to a modular promoter, said modular promoter comprising at least one portion which is derived from a promoter which, in its native form, directs synthesis of an ACC synthase encoded by  
30 a gene comprising a nucleotide sequence substantially as set forth in <400>1 or a nucleotide sequence having at least 50% similarity thereto or a nucleotide

- 6 -

sequence capable of hybridizing to <400>1 under low stringency conditions.

In still yet another aspect of the present invention, there is provided a modular promoter comprising a portion which is derived from a promoter which comprises, in 5 its native form, a nucleotide sequence substantially as set forth in <400>3 or a nucleotide sequence having at least 25% similarity thereto or a nucleotide sequence capable of hybridizing to <400>3 under low stringency conditions.

Another aspect of the present invention contemplates a genetic construct 10 comprising a promoter or modular promoter each as herein defined or a derivative or homologue thereof, means to facilitate insertion of a nucleotide sequence downstream of and operably linked to said promoter and optionally a gene encoding a selectable marker.

15 A further aspect of the present invention provides a genetic construct comprising a promoter or modular promoter each as herein defined or a derivative or homologue thereof, a nucleotide sequence operably linked to said promoter and optionally a gene encoding a selectable marker.

20 Another aspect of the present invention provides an isolated nucleic acid molecule comprising a sequence of nucleotides or a complementary sequence of nucleotides defining a promoter or a derivative or homologue thereof which is capable of constitutive expression in cells in which the promoter is non-indigenous.

25 Yet another aspect of the present invention is directed to an isolated nucleic acid molecule comprising a sequence of nucleotides or a complementary sequence of nucleotides defining a promoter or a derivative or homologue thereof, wherein said promoter, in its native form, directs expression in response to physical stimulation of a gene associated with ethylene production and which promoter in a non-native 30 host cell is constitutively expressed.

Still yet another aspect of the present invention relates to an isolated nucleic acid molecule comprising a sequence of nucleotides or a complementary sequence of nucleotides defining a promoter or a derivative or homologue thereof wherein said promoter, in its native form, directs expression in response to physical stimulation of 5 a gene encoding ACC synthase and which promoter in a non-native host cell is constitutively expressed.

A further aspect of the present invention provides an isolated nucleic acid molecule comprising a sequence of nucleotides or a complementary sequence of nucleotides 10 defining a promoter or a derivative or homologue thereof wherein said promoter, in its native form, directs expression of a gene encoding ACC synthase or another gene associated with ethylene biosynthesis and in a cell in which the promoter is indigenous, the promoter is inducible by physical stimulation whereas in a cell in which the promoter is non-indigenous, the promoter is constitutively expressed.

15

Another aspect of the present invention provides an isolated an isolated acid molecule comprising a sequence of nucleotides or complementary sequence of nucleotides defining a promoter or a derivative or homologue thereof, wherein, in its native form, the promoter is inducible in response to physical stimulation and 20 wherein the promoter is selected from the list consisting of:

(i) a promoter which, in its native form, directs expression of a nucleotide sequence substantially as set forth in <400>1;

25 (ii) a promoter which, in its native form, directs expression of a nucleotide sequence which hybridizes under low stringency conditions to <400>1;

(iii) a promoter which, in its native form, directs expression of a nucleotide sequence having at least about 50% similarity to <400>1;

30

(iv) a promoter which, in its native form, directs expression of a nucleotide

- 8 -

sequence which encodes an amino acid sequence substantially as set forth in  
<400>2;

(v) a promoter which, in its native form, directs expression of a nucleotide  
5 sequence which encodes an amino acid sequence which has at least about 60%  
similarity to <400>2;

(vi) a promoter comprising a nucleotide sequence substantially as set forth in  
<400>3;

10 (vii) a promoter comprising a nucleotide sequence capable of hybridizing to  
<400>3 under low stringency conditions; and

15 (viii) a promoter comprising a nucleotide sequence having at least about 25%  
similarity to <400>3.

#### BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a representation of the oligonucleotide primers used in Long Distance  
20 Inverse PCR.

Figure 2 is a diagrammatic representation showing generation of *Sph*I and *Xba*I  
fragments of pGEL-1.

25 Figure 3 is a diagrammatic representation of pGEL-1 sequencing strategy.

Figure 4 is a representation of the nucleotide sequence of pGEL-1 (2470 bp).

Figure 5 is a diagrammatic representation of the construction of full length pGEL-1.

30

Figure 6A(i) - 6A(xii) are diagrammatic representations of plasmids pPZP2.5GuNt,

- 9 -

pPZP2.5LuNt, pPZP1.4GuNt, pPZP1.4LuNt, pPZP35SGuNt, pPZP35SLuNt, pPZP017GuNt, pPZP023GuNt, pPZP045GuNt, pPZP070GuNt, pPZP088GuNt and pPZP1.1GuNt, respectively. Gu, GUS; Lu, luciferase (LUC); Nt, Nos terminator; 35S, cauliflower mosaic virus 35S promoter. The number given after the term "pPZP" represents the length of the promoter sequence in kilobases. For example, pPZP2.5LuNt contains the full length promoter, pGEL-1.

**Figure 6B** is a diagrammatic representation of the backbone vector pPZP111 (Hajdukiewicz et al, 1994).

10

**Figure 6C** is a diagrammatic representation of the vector pGuNt.

**Figure 7** are photographic representations showing (A) and (B) transgenic tobacco lines containing pGEL-1:GUS gene assayed to visualise GUS activity; and (C) wild-type tobacco stained for GUS (negative control).

**Figures 8(a) and (b)** are graphical representations showing GUS activity in young tobacco plants, transformed with pGEL-1:GUS and CaMV35S:GUS constructs. 2.5G#3-4 and 2.5G#7-3 are two independent transgenic lines containing full length 20 promoter, pGEL-1, fused to the GUS gene; 35SG#5-2 is a transgenic line containing CaMV35S promoter fused to the GUS gene. (A) is GUS activity measured as nmoles Mu per minute per mg protein. (B) is GUS activity measured as nmoles Mu per minute per gram fresh weight (gfw) of plant material. Mu is equal to 4-methyl-umbelliflferone.

25

**Figure 9** is a graphical representation showing quantitative analysis of pGEL-1 and 35S cauliflower mosaic virus (CaMV) promoter: GUS fusions in mature vegetative transgenic tobacco. (A) expressed as nmoles of Mu produced per minute per mg protein; (B) expressed as nmoles of Mu produced per minute per gram fresh weight 30 (gfw) of plant material.

1234567890-/+\*/#

- 10 -

**Figure 10** is a graphical representation showing a quantitative analysis of pGEL1 and 35SCaMV promoter:GUS fusions in mature flowering transgenic tobacco. (A) expressed as nmoles of Mu produced per minute per mg protein; (B) expressed as nmoles of Mu produced per minute per gram fresh weight (gfw) of plant material.

5

**Figure 11** is a graphical representation showing quantitative analysis of a range of deletions of pGEL-1:GUS fusions in mature vegetative transgenic tobacco. Deletions range from 1.027 bp to 86 bp. Activity is expressed as nmoles of Mu produced per minute per gram fresh weight (gfw) of plant material.

10

**Figure 12** is a diagrammatic representation showing deletions in pGEL-1.

**Figure 13** is a photographic representation of Southern analysis of three T2 homozygous independent tobacco transgenic lines (3-4, 7-3 and 10-3) containing 15 pGEL-1 fused to the GUS gene, and one T2 homozygous tobacco transgenic line (5-2) containing the CaMV 35S promoter fused to the GUS gene. Genomic DNA was digested with *Eco*RI (E) or *Bam*HI (B) restriction enzymes. A <sup>32</sup>P-labelled DNA fragment containing the full GUS gene and Nos terminator was used as a probe. Lane 1 contained size markers. Lanes 2 and 3: line 3-4; lanes 4 and 5: line 7-3; 20 lanes 6 and 7: line 10-3; lane 8: line 5-2.

RECEIVED JULY 22 1999  
AUSTRALIAN PCT OFFICE

## **DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS**

The present invention is predicated in part on the identification of a promoter directing expression of a gene. The gene encodes 1-aminocyclopropane-1-  
5 carboxylic acid synthase ("ACC synthase") and is inducible, in its native form, by physical stimuli (Botella et al, 1992; Botella et al, 1995). Reference herein to "native form" with respect to a promoter means the promoter in cells in which the promoter is normally resident, i.e. indigenous. In the present case, cells from mung bean plants are cells in which the promoter is indigenous. When the promoter is  
10 transferred by genetic means to non-mung bean plant cells, the resulting cells are an example of cells carrying a non-indigenous promoter.

Accordingly, the present invention provides an isolated nucleic acid molecule comprising a sequence of nucleotides or a complementary sequence of nucleotides defining a promoter or a derivative or homologue thereof wherein, in its native form, the promoter is inducible in response to physical stimulation.

More particularly, the present invention is directed to an isolated nucleic acid molecule comprising a sequence of nucleotides or a complementary sequence of 20 nucleotides defining a promoter or a derivative or homologue thereof, wherein said promoter, in its native form, directs expression of a gene associated with ethylene production and is inducible by physical stimulation.

Even more particularly, the present invention relates to an isolated nucleic acid  
25 molecule comprising a sequence of nucleotides or a complementary sequence of  
nucleotides defining a promoter or a derivative or homologue thereof wherein said  
promoter, in its native form, directs expression of a gene encoding ACC synthase  
and is inducible by physical stimulation.

30 In a related embodiment, the present invention relates to an isolated nucleic acid molecule comprising a sequence of nucleotides or a complementary sequence of

- 12 -

nucleotides defining a promoter or a derivative or homologue thereof wherein said promoter, in its native form, directs expression of a gene encoding ACC synthase or another gene associated with ethylene biosynthesis and is inducible by physical stimulation.

5

Although the present invention is exemplified by the identification and isolation of the promoter directing synthesis of ACC synthase from *Vigna radiata* (mung bean), the present invention extends to any promoter which, in its native form, is inducible in response to physical stimulation and which directs expression of a nucleotide sequence having at least about 50% similarity to the nucleotide sequence set forth in <400>1 and/or nucleotide sequence capable of hybridizing to the nucleotide sequence of <400>1 under low stringency conditions, such as at 42°C.

10 Examples of promoters contemplated by the present invention include but are not limited to promoters directing expression of genes associated with ethylene biosynthesis such as the gene encoding ACC synthase.

15 The gene encoding ACC synthase from mung bean is referred to as AIM-1. ACC synthase from mung bean comprises the amino acid sequence substantially as set forth in <400>2.

20 Accordingly, another aspect of the present invention is directed to an isolated nucleic acid molecule comprising a sequence of nucleotides or a complementary sequence of nucleotides defining a promoter or a derivative or homologue thereof wherein said promoter, in its native form, directs expression of a gene encoding an ACC synthase having an amino acid sequence substantially as set forth in <400>2 or an amino acid sequence having at least 60% similarity to <400>2.

25 The percentage similarity at the amino acid or nucleotide sequence level is generally to a portion comprising at least about 20 contiguous amino acids or at least about 60 contiguous nucleotide bases. Preferably, however, the comparison

is made to the entire amino acid sequence or entire nucleotide sequence.

Alternative percentage similarities include at least about 70%, at least about 80%, at least about 90% and at least about 95% or above or discrete percentages there between.

5

Genes encoding ACC synthase enzymes not having 100% similarity to <400>2 include derivatives and homologous of the mung bean enzyme. A derivative includes parts, fragments, mutants and fusions of the mung bean ACC synthase defined in <400>2 including ACC synthase enzymes having one or more amino

10 acid substitutions, additions and/or deletions to the amino acid sequence of <400>2. Homologues include enzymes from closely or distantly related plants including fungi.

A particularly preferred promoter of the present invention directs expression of AIM-

15 1. The nucleotide sequence of AIM-1 is set forth in <400>1.

According to this embodiment, there is provided an isolated nucleic acid molecule comprising a sequence of nucleotides or a complementary sequence of nucleotides defining a promoter or a derivative or homologue thereof wherein said promoter in 20 its native form directs expression of a gene encoding ACC synthase and wherein said gene comprises a nucleotide sequence substantially as set forth in <400>1 or a sequence having at least 50% similarity thereto and/or a nucleotide sequence capable of hybridizing to <400>1 under low stringency conditions, such as at 42°C.

25 For the purposes of defining the level of stringency, those skilled in the art will be aware that several different hybridization conditions may be employed. For example, a low stringency may comprise a hybridization and/or a wash carried out in 6xSSC buffer, 0.1% w/v SDS at from about room temperature to about 44°C such as from about 28°C to about 42°C or equivalent condition sufficient for 30 annealing of primers in a polymerase chain reaction or hybridization of oligonucleotide to DNA or RNA. A medium stringency may comprise a

- 14 -

hybridization and/or wash carried out in 2xSSC buffer, 0.1% w/v SDS at a temperature in the range of from about 45°C to about 65°C. A high stringency may comprise a hybridization and/or wash carried out in 0.1xSSC buffer, 0.1% w/v SDS at a temperature of at least about 65°C. The buffers may also contain from 0% to 5 about 10 to about 15% v/v formamide for use in the hybridization and/or washing solutions.

Generally, the stringency is increased by reducing the concentration of SSC buffer, and/or increasing the concentration of SDS in the hybridization buffer or wash 10 buffer and/or increasing the temperature at which the hybridization and/or wash are performed. Conditions for hybridizations and washes are well understood by one normally skilled in the art. For the purposes of clarification of parameters affecting hybridization between nucleic acid molecules, reference can conveniently be made to pages 2.10.8 to 2.10.16 of Ausubel et al (1987), which is herein incorporated by 15 reference.

Alternative percentage similarities include those set forth above.

Nucleotide sequences not having 100% similarity to <400>1 include derivatives and 20 homologues of mung bean A/M-1. A derivative includes, parts, fragments, mutants and fusions of the mung bean A/M-1 defined in <400>1 including A/M-1 genes having one or more nucleotide substitutions, additions and/or deletions to the nucleotide sequence of <400>1. Homologues include genes from closely or distantly related plants including fungi.

25 The term "similarity" as used herein includes exact identity between compared sequences at the nucleotide or amino acid level. Where there is non-identity at the nucleotide level, "similarity" includes differences between sequences which result in different amino acids that are nevertheless related to each other at the structural, 30 functional, biochemical and/or conformational levels. Where there is non-identity at the amino acid level, "similarity" includes amino acids that are nevertheless related

- 15 -

to each other at the structural, functional, biochemical and/or conformational levels. In a particularly preferred embodiment, nucleotide and sequence comparisons are made at the level of identity rather than similarity. Any number of programs are available to compare nucleotide and amino acid sequences. Preferred programs 5 have regard to an appropriate alignment. One such program is Gap which considers all possible alignment and gap positions and creates an alignment with the largest number of matched bases and the fewest gaps. Gap uses the alignment method of Needleman and Wunsch (1970). Gap reads a scoring matrix that contains values for every possible GCG symbol match. GAP is available on 10 ANGIS (Australian National Genomic Information Service) at website <http://mel1.angis.org.au>.

Most preferably, the promoter of the present invention comprises a nucleotide sequence substantially as set forth in <400>3 or a functional derivative or 15 homologue thereof.

Accordingly, another aspect of the present invention is directed to an isolated nucleic acid molecule comprising a sequence of nucleotides or a complementary sequence of nucleotides defining a promoter or a derivative or homologue thereof 20 wherein said promoter in its native form comprises a nucleotide sequence substantially as set forth in <400>3 or a nucleotide sequence having at least 25% similarity thereto or a nucleotide sequence capable of hybridizing to <400>3 under low stringency conditions such as at 42°C.

25 Still another aspect of the present invention provides an isolated nucleic acid molecule comprising a sequence of nucleotides or complementary sequence of nucleotides defining a promoter or a derivative or homologue thereof, wherein, in its native form, the promoter is inducible in response to physical stimulation and wherein the promoter is selected from the list consisting of:

30

- (i) a promoter which, in its native form, directs expression of a nucleotide

- 16 -

sequence substantially as set forth in <400>1;

(ii) a promoter which, in its native form, directs expression of a nucleotide sequence which hybridizes under low stringency conditions to <400>1;

5

(iii) a promoter which, in its native form, directs expression of a nucleotide sequence having at least about 50% similarity to <400>1;

(iv) a promoter which, in its native form, directs expression of a nucleotide sequence which encodes an amino acid sequence substantially as set forth in <400>2;

(v) a promoter which, in its native form, directs expression of a nucleotide sequence which encodes an amino acid sequence which has at least about 60% similarity to <400>2;

(vi) a promoter comprising a nucleotide sequence substantially as set forth in <400>3;

20 (vii) a promoter comprising a nucleotide sequence capable of hybridizing to <400>3 under low stringency conditions; and

(viii) a promoter comprising a nucleotide sequence having at least about 25% similarity to <400>3.

25

The determination of low stringency conditions may be done from about room temperature to about 44°C. Preferably, low stringency is determined at 28°C. Alternatively, low stringency is determined at 42°C.

30 The promoter of the present invention is useful in the development of genetic constructs to express heterologous nucleotide sequences placed downstream of,

and operably linked to, the promoter.

Reference herein to a "promoter" is to be taken in its broadest context and includes the transcriptional regulatory sequences of a classical genomic gene, including the 5 TATA box which is required for accurate transcription initiation, with or without a CCAAT box sequence and additional regulatory elements (i.e. upstream activating sequences, enhancers and silencers) which alter gene expression in response to developmental and/or environmental stimuli, or in a tissue-specific or cell-type-specific manner. A promoter is usually, but not necessarily, positioned upstream of 10 or 5' to a structural gene, the expression of which it regulates. Furthermore, the regulatory elements comprising a promoter are usually positioned within 2 kb of the start site of transcription of the gene.

In the present context, the term "promoter" is also used to describe a synthetic or 15 fusion molecule, or derivative which confers, activates or enhances expression of a structural gene or other nucleic acid molecule in a plant cell.

The term "operably in connection" or "operably linked to" in the present context means placing a structural gene under the regulatory control of the promoter of the 20 present invention by positioning the structural gene such that the expression of the gene is controlled by the promoter. Promoters and the like are generally positioned 5' (upstream) to the genes that they control. In the construction of heterologous promoter/structural gene combinations, it is generally preferred to position the promoter at a distance from the gene transcription start site that is approximately 25 the same as the distance between that genetic sequence or promoter and the gene it controls in its natural setting, i.e., the gene from which the promoter is derived. As is known in the art, some variation in this distance can be accommodated without loss of function.

30 As used herein, a "structural gene" shall be taken to refer to that portion of a gene comprising a DNA segment encoding a protein, polypeptide or a portion thereof or

alternatively, an isolated nucleic acid molecule which does not necessarily encode a polypeptide, such as an antisense, ribozyme, abzyme or co-suppression molecule.

- 5 The term "structural gene" also refers to copies of a structural gene naturally found within the cell, but artificially introduced, or the structural gene may encode a protein not normally found in the plant cell into which the gene is introduced, in which case it is termed a heterologous gene. A heterologous structural gene may be derived in whole or in part from a bacterial genome or episome, eukaryotic
- 10 genomic or plastid DNA, cDNA, viral DNA, or chemically synthesized DNA. It is possible that a structural gene may contain one or more modifications in either the coding or the untranslated regions which affect the biological activity or the chemical structure of the expression product, the rate of expression, or the manner of expression control. Such modifications include, but are not limited to, mutations,
- 15 insertions, deletions, and substitutions of one or more nucleotides.

Where the structural gene encodes a polypeptide, it may constitute an uninterrupted coding sequence or it may include one or more introns, bounded by the appropriate plant-functional splice junctions. The structural gene may be a

- 20 composite of segments derived from a plurality of sources, naturally occurring or synthetic. The structural gene may also encode a fusion protein, as long as the experimental manipulations maintain functionality in the joining of the coding sequences.
- 25 Another aspect of the invention relates to the use of the promoter of the present invention or a derivative or homologue or modular form thereof in the identification and/or isolation of similar promoter sequences associated with other genes.

According to this embodiment, there is contemplated a method for identifying a

- 30 related nucleic acid molecule which is at least capable of conferring, increasing or otherwise facilitating the expression of a structural gene, when in native form, in

- 19 -

response to physical stimulation, said method comprising contacting genomic DNA or parts or fragments thereof, with a hybridization-effective amount of the nucleotide sequence set forth in <400>1 or <400>3, or a part, analogue or derivative thereof or a complementary sequence thereto, and then detecting said hybridization.

5

Another aspect of the present invention contemplates a nucleic acid molecule defining a promoter or a homologue or derivative thereof said nucleic acid molecule obtainable by the method of isolating genomic DNA from plant cells, rendering the genomic DNA or portion thereof single stranded and then identifying a region on 10 genomic DNA which hybridizes to a primer corresponding to all or part of <400>1 or a complementary form thereof and then cloning DNA upstream of the region of primer hybridization.

The related genetic sequence may be in a recombinant form, in a virus particle, 15 bacteriophage particle, yeast cell, animal cell, or a plant cell. Preferably, the related genetic sequence originates from an agriculturally-important or horticulturally- important plant such as potato, tomato, wheat, barley, canola, oats, maize, sugar cane, cotton or rice and/or wild varieties and/or hybrids or derivatives and/or ancestral progenitors of same. Horticulturally important plants include rose, 20 carnation, petunia, lisianthus, lily, iris, tulip, freesia, delphinium, limonium, pelargonium as well as fruit and vegetable crops such as papaya.

The present invention clearly extends to an isolated nucleic acid molecule which comprises a sequence of nucleotides which overlaps with the sequence set forth in 25 <400>1 or <400>3.

Preferably, such isolated nucleic acid molecules comprise genomic DNA which is isolated using polymerase chain reaction or hybridization approaches based upon the nucleotide information disclosed in <400>1 or <400>3.

30

Preferably, the genetic sequence set forth in <400>1 or <400>3, or a derivative or

- 20 -

analogue thereof, is labelled with a reporter molecule capable of producing an identifiable signal (e.g. a radioisotope such as  $^{32}\text{P}$ , or  $^{35}\text{S}$ , or a biotinylated molecule) to facilitate its use as a hybridization probe in the isolation of related nucleic acid molecules.

5

An alternative method contemplated in the present invention involves hybridising a nucleic acid primer molecule of at least 10 nucleotides in length, derived from <400>1 or <400>3, or a derivative or analogue thereof, to a nucleic acid "template molecule", said template molecule herein defined as for example, genomic DNA, or 10 a functional part thereof. Specific nucleic acid molecule copies of the template molecule are amplified enzymatically in a polymerase chain reaction, a technique that is well known to one skilled in the art.

Preferably, the nucleic acid primer molecule or molecule effective in hybridization is 15 contained in an aqueous mixture of other nucleic acid primer molecules. More preferably, the nucleic acid primer molecule is in a substantially pure form.

The nucleic acid template molecule may be in a recombinant form, in a virus particle, bacteriophage particle, yeast cell, animal cell, or a plant cell. Preferably, 20 the related genetic sequence originates from an agricultural or horticultural plant or other suitable plant species.

The present invention extends to the subject promoter in a genetic construct.

25 The term "genetic construct" is used in its broadest sense to include an isolated nucleic acid molecule comprising a sequence of nucleotides.

The genetic construct is conveniently engineered so as to include means to facilitate insertion of a nucleotide sequence in a region 3' of the promoter, to place 30 a nucleotide sequence downstream of and operably linked to, the promoter which then directs its transcription. Such a "means" includes but is not limited to a

- 21 -

restriction endonuclease-mediated insertion, homologous recombination, transposon insertion, PCR mediated insertion and random insertion. Preferably, the means is a restriction endonuclease site. Generally, the inserted restriction site is unique to the genetic construct or may be represented, for example, twice but 5 separated by a nucleic acid sequence which is deleted upon restriction digestion of the genetic construct. The required nucleotide sequence to be transcribed is then inserted into the deleted region.

The genetic construct of the present invention may comprise solely the promoter 10 and optionally a nucleotide sequence downstream thereof or, alternatively, may comprise additional nucleotide sequences constituting promoter regulatory region(s), transcribed sequence regulatory regions, a marker (eg. antibiotic resistance, chemical compound resistance or enzyme such as  $\beta$ -galactosidase (GUS) or luciferase (LUC)  $\beta$ -glucuronidase), autonomous replication region and/or 15 genome integration sequence. The promoter may be the naturally occurring promoter or may be an active fragment or part thereof or a derivative, analogue or homologue of the promoter.

Accordingly, another aspect of the present invention contemplates a genetic 20 construct comprising a promoter or modular promoter each as herein defined or a derivative or homologue thereof, means to facilitate insertion of a nucleotide sequence operably linked to said promoter and optionally a gene encoding a selectable marker.

25 More particularly, this aspect provides a genetic construct comprising a promoter or modular promoter as herein defined or a derivative or homologue thereof, one or more unique restriction sites down stream of said promoter to enable the insertion of a heterologous nucleotide sequence operably linked to said promoter and a gene encoding a selectable marker.

30

In a related embodiment, the present invention provides a genetic construct

- 22 -

comprising a promoter or modular promoter each as herein defined or a derivative or homologue thereof, a nucleotide sequence operably linked to said promoter and optionally a gene encoding a selectable marker.

5 The present invention extends to genetic constructs in which the genetic sequence of the invention, or a functional derivative, part, fragment, homologue, or analogue thereof, is operably linked to a structural gene sequence. The invention is not, however, limited by the nature of the structural gene sequence contained in such genetic constructs.

10

In one embodiment, the structural gene sequence is a reporter gene, such as but not limited to the  $\beta$ -glucuronidase gene, or the chloramphenicol acetyl transferase gene, or the firefly luciferase gene, amongst others.

15 In an alternative embodiment, the structural gene sequence encodes, or is complementary to a structural gene sequence encoding, a cytotoxin or other gene product which, when produced in a plant cell, kills or significantly alters host cell metabolism to limit cell division.

20 In a further alternative embodiment, the structural gene sequence encodes, or is complementary to a structural gene sequence encoding, a hormone polypeptide or polypeptide which is involved in the biosynthesis of a hormone or other molecule. The invention particularly contemplates the expression of a phytohormone molecule under control of the promoter defined in <400>3 or an analogue or derivative

25 thereof, to produce a high local concentration of said phytohormone in the undifferentiated cells which is sufficient to result in the development of a floral meristem or vegetative meristem, depending upon the nature of the phytohormone.

30 In a still further alternative embodiment, the structural gene sequence may be a ribozyme, abzyme, antisense or co-suppression molecule which targets the expression of a gene. According to this embodiment, expression of such a

- 23 -

structural gene under the control of the genetic sequence of the invention will partially or completely reduce, delay or inhibit the expression of said structural gene.

5 Yet another alternative embodiment comprises a structural gene whose product facilitates the accumulation of a molecule which itself or a further metabolic or oxidised form thereof facilitates a change in the colour of plant tissue, cells, organs, leaves or flowers. For example, the structural gene may encode a flavonoid pathway enzyme or a cytochrome P450 molecule such as a plant, mammalian or

10 bacterial monooxygenase.

Wherein the structural gene being targeted is normally expressed in more than one cell type, the expression of said structural gene under control of the promoter of the present invention may further result in the gene being expressed in a cell-type or  
15 tissue-type specific pattern.

The genetic construct according to this aspect of the invention may further comprise a transcription termination sequence, placed operably in connection with the structural gene sequence.

20 In an alternative embodiment, the transcription termination sequence is placed downstream of the promoter of the present invention, optionally spaced therefrom by a nucleotide sequence which comprises one or more restriction endonuclease recognition sites, to facilitate the insertion of a structural gene sequence as  
25 hereinbefore defined between said genetic sequence and said transcription termination sequence.

The term "terminator" refers to a DNA sequence at the end of a transcriptional unit which signals termination of transcription. Terminators are 3'-non-translated DNA  
30 sequences containing a polyadenylation signal, which facilitates the addition of polyadenylate sequences to the 3'-end of a primary transcript. Terminators active

- 24 -

in cells derived from viruses, yeasts, moulds, bacteria, insects, birds, mammals and plants are known and described in the literature. They may be isolated from bacteria, fungi, viruses, animals and/or plants.

- 5 Examples of terminators particularly suitable for use in the genetic constructs of the present invention include the nopaline synthase (NOS) gene terminator of *Agrobacterium tumefaciens*, the terminator of the Cauliflower mosaic virus (CaMV) 35S gene, the zein gene terminator from *Zea mays*, the Rubisco small subunit (SSU) gene terminator sequences, subclover stunt virus (SCSV) gene sequence  
10 terminators, any rho-independent *E. coli* terminator, amongst others.

The genetic construct of the instant invention may further include an origin of replication sequence which is required for replication in a specific cell type, for example a bacterial cell, when said genetic construct is required to be maintained  
15 as an episomal genetic element (eg. plasmid or cosmid molecule) in said cell.

Preferred origins of replication include, but are not limited to, the *f1*-ori and *coIE1* origins of replication.

- 20 In a further alternative embodiment, the genetic construct of the invention further comprises one or more selectable marker genes or reporter gene sequences, placed operably in connection with a suitable promoter sequence which is operable in a plant cell and optionally further comprising a transcription termination sequence placed downstream of said selectable marker gene or reporter gene sequences.  
25

As used herein, the term "selectable marker gene" includes any gene which confers a phenotype on a cell in which it is expressed to facilitate the identification and/or selection of cells which are transfected or transformed with a genetic construct of the invention or a derivative thereof.

- 30 Suitable selectable marker genes contemplated herein include the ampicillin

- 25 -

resistance gene (Amp'), tetracycline resistance gene (Tc'), bacterial kanamycin resistance gene (Kan'), phosphinothricin resistance gene, neomycin phosphotransferase gene (*nptII*), hygromycin resistance gene,  $\beta$ -glucuronidase (GUS) gene, chloramphenicol acetyltransferase (CAT) gene and luciferase gene,  
5 amongst others.

Those skilled in the art will be aware that the choice of promoter for expressing a selectable marker gene or reporter gene sequence may vary depending upon the level of expression required and/or the species from which the host cell is derived  
10 and/or the tissue-specificity or development-specificity of expression which is required.

Examples of promoters suitable for use in expressing selectable marker or reporter gene in the genetic constructs of the present invention include promoters derived  
15 from the genes of viruses, yeasts, moulds, bacteria, insects, birds, mammals and plants which are capable of functioning in isolated plant cells or whole organisms regenerated therefrom, including whole plants. The promoter may regulate the expression of the selectable marker gene or reporter gene constitutively, or differentially with respect to the tissue in which expression occurs, or with respect to  
20 the developmental stage at which expression occurs, or in response to external stimuli such as physiological stresses, pathogens, or metal ions, amongst others.

Examples of promoters include the CaMV 35S promoter, NOS promoter, octopine synthase (OCS) promoter, *Arabidopsis thaliana* SSU gene promoter, napin seed-specific promoter, P<sub>32</sub> promoter, BK5-T imm promoter, lac promoter, tac promoter, phage lambda  $\lambda_L$   $\lambda_R$  or promoters, CMV promoter (U.S. Patent No. 5,168,062), T7 promoter, lacUV5 promoter, SV40 early promoter (U.S. Patent No. 5,118,627), SV40 late promoter (U.S. Patent No. 5,118,627), adenovirus promoter, baculovirus P10 or polyhedrin promoter (U.S. Patent Nos. 5,243,041; 5,242,687; 5,266,317;  
30 4,745,051; and 5,169,784), and the like. In addition to the specific promoters identified herein, cellular promoters for so-called housekeeping genes are useful.

- 26 -

Those skilled in the art will be aware of additional promoter sequences and terminator sequences which may be suitable for use in performing the invention. Such sequences may readily be used without any undue experimentation.

5 A still further embodiment contemplates a genetic construct which further comprises one or more integration sequences.

As used herein, the term "integration sequence" shall be taken to refer to a nucleotide sequence which facilitates the integration into plant genomic DNA of a 10 genetic sequence of the invention with optional other integers referred to herein.

Particularly preferred integration sequences according to this embodiment include the left border (LB) and right border (RB) sequences of T-DNA derived from the Ti plasmid of *Agrobacterium tumefaciens* or a functional equivalent thereof.

15

Another aspect of the invention provides a method of expressing a structural gene in a plant cell, said method comprising introducing into said plant cell a genetic construct comprising a promoter sequence which is at least capable of conferring, increasing or otherwise regulating expression of a structural gene to which it is 20 operably connected in a plant cell, wherein said promoter sequence preferably comprises the nucleotide sequence set forth in <400> 3, or a functional derivative, part, fragment, homologue, or analogue thereof which is at least 25% similar thereto or a complementary sequence thereto or a sequence capable of hybridising to <400>3 under low stringency conditions such as 28°C or 42°C and wherein said 25 structural gene is operably linked to said promoter sequence on said genetic construct.

The method according to this aspect of the invention is particularly useful for the expression of a wide range of foreign structural genes in cells of plants, including a 30 cell cycle control protein; an antibody-expressing gene, such as a SCAB gene; a selectable marker gene that confers resistance against kanamycin,

PCT/AU99/00705

- 27 -

phosphinothricin, spectinomycin or hygromycin, amongst others; a reporter gene including GUS, CAT, LUC and pigment genes, amongst others; a gene encoding a regulatory protein which modulates expression of a gene in plant cells; and a gene which encodes a developmental regulatory protein, such as, for example, a 5 homeobox protein, that is involved in regulating the developmental fate of a cell. As will be apparent from the disclosure herein, the present method is clearly applicable to the expression of antisense molecules, ribozyme molecules, co-suppression molecules, gene-targeting molecules, or other molecules that are intended to modulate the expression of one or more endogenous plant genes.

10

A further aspect of the present invention provides a transfected or transformed cell, tissue, organ or whole organism which comprises the promoter or its derivatives or homologues of the present invention. Preferably, the cell, tissue, organ or whole organism expresses a structural gene operably under the control of said promoter 15 sequence.

This aspect of the invention clearly encompasses a transgenic plant such as a crop plant or flowering plant, transformed with a recombinant DNA molecule which comprises at least a genetic sequence which is at least 25% similar to <400>3.

20

The genetic construct of the present invention may be introduced into a cell by various techniques known to those skilled in the art. The technique used may vary depending on the known successful techniques for that particular organism.

25

Means for introducing recombinant DNA into bacterial cells, yeast cells, or plant, insect, fungal (including mould), avian or mammalian tissue or cells include, but are not limited to, transformation using  $\text{CaCl}_2$  and variations thereof, direct DNA uptake into protoplasts, PEG-mediated uptake to protoplasts microparticle bombardment, electroporation, microinjection of DNA, microparticle bombardment of tissue

30

explants or cells, vacuum-infiltration of tissue with nucleic acid, or in the case of plants, T-DNA-mediated transfer from *Agrobacterium* to the plant tissue.

For microparticle bombardment of cells, a microparticle is propelled into a cell to produce a transformed cell. Any suitable ballistic cell transformation methodology and apparatus can be used in performing the present invention. Exemplary apparatus and procedures are disclosed by Stomp *et al.* (U.S. Patent No. 5 5,122,466) and Sanford and Wolf (U.S. Patent No. 4,945,050). When using ballistic transformation procedures, the genetic construct may incorporate a plasmid capable of replicating in the cell to be transformed.

Examples of microparticles suitable for use in such systems include 0.1 to 10  $\mu\text{m}$  10 gold or tungsten spheres such as a 0.5-5  $\mu\text{m}$  gold or tungsten sphere. The DNA construct may be deposited on the microparticle by any suitable technique, such as by precipitation.

Once introduced into the plant tissue, the expression of a structural gene under 15 control of the promoter of the present invention may be assayed in a transient expression system, or it may be determined after selection for stable integration within the plant genome.

Where the cell is derived from a multicellular organism and where relevant 20 technology is available, a whole organism may be regenerated from the transformed cell, in accordance with procedures well known in the art.

Those skilled in the art will be aware of the methods for transforming, regenerating and propagating other type of cells, such as those of fungi.

25 In the case of plants, plant tissue capable of subsequent clonal propagation, whether by organogenesis or embryogenesis, may be transformed with a genetic construct of the present invention and a whole plant regenerated therefrom. The particular tissue chosen will vary depending on the clonal propagation systems 30 available for, and best suited to, the particular species being transformed. Exemplary tissue targets include leaf disks, pollen, embryos, cotyledons,

- 29 -

hypocotyls, megagametophytes, callus tissue, existing meristematic tissue (e.g., apical meristem, axillary buds, and root meristems), and induced meristem tissue (e.g., cotyledon meristem and hypocotyl meristem).

5 The regenerated transformed plants may be propagated by a variety of means, such as by clonal propagation or classical breeding techniques. For example, a first generation (or T1) transformed plant may be selfed to give homozygous second generation (or T2) transformants, and the T2 plants further propagated through classical breeding techniques.

10

The regenerated transformed cells contemplated herein may take a variety of forms. For example, they may be chimeras of transformed cells and non-transformed cells; clonal transformants (e.g., all cells transformed to contain the expression cassette); grafts of transformed and untransformed tissues (e.g., in

15 plants, a transformed root stock grafted to an untransformed scion ).

The promoter of the present invention, in its native form (i.e. in cells in which it is indigenous), is inducible by physical stimulus which includes mechanical stress, movement, vibration, air pressure, water stress and the like. Other non-mechanical 20 stimuli also induce the instant promoter including auxins, abscisic acid, salt concentration amongst others. Non-mechanical stimuli include environmental stimuli such as but not limited to chemical induction of the promoter. The promoter may also be developmentally regulated and/or may be tissue or organ specific.

25 As stated above, the identification of a promoter capable of induction by physical or mechanical stimuli provides a particularly useful basis for developing a range of genetically altered plants. For example, air movement may be used to activate expression of a nucleotide sequence operably linked to the subject promoter. This may be useful during the commercial cultivation of large numbers of plants.

30 Generating air movement such as generated by fanning, or a change in air pressure over and/or around the plants can be used to activate expression of the

- 30 -

promoter. Alternatively, or in addition, water droplets generated mechanically or by controlling humidity may be used to stimulate promoter activity. Heterologous nucleotide sequences operably linked to the promoter are then expressed. Such heterologous sequences may encode, for example, resistance to insect or other 5 pathogens, salt tolerance, enzymes which manipulate the flow of metabolites down particular biochemical pathways, enzymes which alter the nutritional content of certain types of plant tissues including seeds and other reproductive parts and antisense, co-suppression, ribozyme or deoxyribozyme molecules to down regulate expression of an endogenous gene. Examples of the latter would be to 10 render a plant male or female sterile, to alter biochemical pathways or to otherwise alter the characteristics of the target plant, such as to inhibit ethylene biosynthesis or to delay senescence.

Accordingly, another aspect of the present invention contemplates a method of 15 altering a characteristic of a plant said method comprising introducing a genetic construct into a cell or group of cells of a plant, said genetic construct comprising a promoter as herein defined and a nucleotide sequence operably linked to said promoter and wherein said nucleotide sequence facilitates the altering of said plant characteristic, regenerating a plant or plantlet from said cell or group of cells 20 carrying said genetic construct and growing or subjecting said plant or plantlet to conditions sufficient to induce the promoter in said genetic construct.

The genetically altered plant may be subjected to physical stimulus such as mechanical stress in order to induce the promoter. Alternative forms of stimulus, 25 however, are also contemplated by the subject invention such as water droplets, air movement, air pressure and chemical stimuli such as auxins. The promoter may also be constitutively expressed.

An altered characteristic may be readily determined by comparing a transgenic 30 plant with a non-transgenic plant of the same species. The comparison may be at the biochemical, physiological or visual level. Altered characteristics include but are

- 31 -

not limited to resistance to plant viruses, bacteria, fungi, nematodes and other pathogens, improved nutritional value (eg. using sunflower high sulphur gene), an expression of an "antibody" (often referred to as a "plantabody"), altered biochemical pathways, altered fertility, altered flower colour amongst many other  
5 characteristics.

The promoter of the present invention is in its native form, inducible by a range of stimuli including physical, environmental, chemical and genetic. The promoter comprises, therefore, different regulatory areas for different stimuli. The present  
10 invention contemplates the manipulation of the subject promoter such that it is inducible by a particular stimulus or stimuli.

Accordingly, another aspect of the present invention provides a modular promoter, said modular promoter comprising at least one portion which is derived from a  
15 promoter which, in its native form, directs expression of a gene associated with ethylene biosynthesis and is inducible by physical stimulation.

More particularly, the present invention is directed to a modular promoter, said modular promoter comprising at least one portion which is derived from a promoter  
20 which, in its native form, directs synthesis of an ACC synthase having an amino acid sequence substantially as set forth in <400>2 or an amino acid sequence having at least 60% similarity thereto.

Even more particularly, the present invention is directed to a modular promoter,  
25 said modular promoter comprising at least one portion which is derived from a promoter which, in its native form, directs synthesis of an ACC synthase encoded by a gene comprising a nucleotide sequence substantially as set forth in <400>1 or a nucleotide sequence having at least 50% similarity thereto or a nucleotide sequence capable of hybridizing to <400>1 under low stringency conditions.

30

Still more particularly, the present invention provides a modular promoter

- 32 -

comprising a portion which is derived from a promoter which comprises, in its native form, a nucleotide sequence substantially as set forth in <400>3 or a nucleotide sequence having at least 25% similarity thereto or a nucleotide sequence capable of hybridizing to <400>3 under low stringency conditions.

5

Low stringency may be determined at about room temperature to about 44°C such as at 28°C to 42°C (e.g. 28°C or 42°C).

A "modular" promoter is considered as an example of a "derivative". Another 10 derivative contemplated by the present invention includes the deletion of negatively acting *cis* element(s). This aspect of the present invention is predicated on the observation of high expression of the promoter in the presence of the protein synthesis inhibitor, cycloheximide, which inhibits production of a highly unstable, short-lived negative regulator (transcription factor) of the subject promoter. 15 Accordingly, by deleting the negative *cis* element(s), higher inducible or even constitutive expression of the promoter may be obtained.

Another aspect of the present invention contemplates an isolated nucleic acid molecule comprising a sequence of nucleotides or a complementary sequence of 20 nucleotides defining a promoter or a derivative or homologue thereof which is capable of constitutive expression in cells in which the promoter is non-indigenous.

This aspect of the present invention is predicated on the surprising observation that the promoter of the present invention, when placed in plant cells in which it is not 25 indigenous, i.e. non-mung bean cells, is constitutively expressed. Although not intending to limit the present invention to any one theory or mode of action, it is proposed that in cells in which the promoter is indigenous, a negative regulatory molecule prevents constitutive expression of the promoter. This negative regulatory molecule would not normally be present in other plant cells and, hence, 30 the promoter is constitutively expressed.

INTERNATIONAL  
PATENT PUBLISHING  
AGENCY  
WIPO

- 33 -

Accordingly, another aspect of the present invention provides an isolated nucleic acid molecule comprising a sequence of nucleotides or a complementary sequence of nucleotides defining a promoter or a derivative or homologue thereof, wherein said promoter, in its native form, directs expression in response to physical stimulation of a gene associated with ethylene production and in which in a non-native host cell is constitutively expressed.

More particularly, a further aspect of the present invention is directed to an isolated nucleic acid molecule comprising a sequence of nucleotides or a complementary sequence of nucleotides defining a promoter or a derivative or homologue thereof wherein said promoter, in its native form, directs expression of a gene encoding ACC synthase or another gene associated with ethylene biosynthesis and in a cell in which the promoter is indigenous, the promoter is inducible by physical stimulation whereas in a cell in which the promoter is non-indigenous, the promoter is constitutively expressed.

- 34 -

The present invention further contemplates a transgenic plant carrying the promoter of the present invention or parts, limbs, flowers, petals, reproductive portions or seeds thereof or progeny or clones thereof.

5 The present invention is further described by the following non-limiting Examples.

**EXAMPLE 1**  
**Detection of mechanical strain-induced gene**

10 A gene encoding 1-aminocyclopropane-1-carboxylic acid synthase ("ACC synthase"), induced *inter alia* by mechanical strain, auxin and salt stress was isolated according to Botella *et al* (1992;1995). The cDNA sequence and corresponding amino acid sequence is shown in <400>1. The amino acid sequence alone is shown in <400>2. This gene is referred to herein as *A/M-1*. Its  
15 promoter is referred to herein as "pGEL-1".

**EXAMPLE 2**  
**Cloning of the ACC Synthase gene (*A/M-1*) promoter (pGEL-1)**

20 (a) Recirculation of DNA

Ten micrograms of genomic DNA isolated by CsCl purification was digested with 2.5 U/ $\mu$ g of *Hind*III in the presence of 0.1 M spermidine, extracted with 1 volume phenol:chloroform:isamyl alcohol (25:24:1) and precipitated by addition of 0.1 vol NaOAc and 2 volumes EtOH. DNA was then re-ligated with 9 Weiss units of T4  
25 DNA ligase and purified using Bresatec's Bresa Clean Kit. The effectiveness of recircularisation was analyzed by gel electrophoresis.

(b) Long Distance Inverse Polymerase Chain Reaction (LDIPCR) procedure

A reaction mixture of 2 mM MgSO<sub>4</sub>, pH 9.1, containing 60 mM Tris-SO<sub>4</sub> and a small  
30 number, e.g. see MgSO<sub>4</sub>, 18 mM (NH<sub>4</sub>)<sub>2</sub> SO<sub>4</sub>, 0.2 mM of each dNTP, 0.2  $\mu$ M of NSE oligonucleotide primers (see Figure 1), sterile water and 300 ng of recircularised

- 35 -

genomic DNA was prepared in a total volume of 40  $\mu$ l. The reaction mixture was vortexed and briefly spun prior to incubation at 94°C to prevent non-specific primer interactions. Before initialising the thermal cycle, 10  $\mu$ l of sterile water containing 1  $\mu$ l of Life Technologies' eLONGase enzyme mix (TaqI/Vent polymerases) was added to the reaction and mixed by pipetting. An equal volume of mineral oil was layered over the mix to prevent evaporation. The optimised PCR parameters are shown in Table 1.

**TABLE 1**

10 PCR profile times and temperatures used during amplification and reamplification protocols.

<b>Optimised Temperatures and Times</b>					
15	Amplification	Initial Step	Denaturation	Anneal and Extension	
		60 sec. 94°C	30 sec. 94°C	480 sec. 68°C	
		45 cycles			
	Reamplification	Initial Step	Denaturation	Anneal	Extension
		60 sec. 94°C	30 sec.	30 sec.	480 sec.
			94°C	62°C	68°C
		35 cycles			

20

After the final step of thermal cycling, 1 volume of chloroform-isoamyl alcohol (24:1) was added to remove the oil layer and the samples were stored at 4°C.

#### 25 Cloning Strategy

The circularised genomic DNA was first amplified with oligonucleotide primers NSE-1 and NSE-2 (refer to Figure 1). The products of this first amplification were further reamplified using either NSE-3/NSE-4 or NSE-5/NSE-6 (Figure 1). Electrophoretic

- 36 -

analysis of the amplification products, generated with both combinations of primers, revealed a DNA fragment of approximately 4 kb.

### EXAMPLE 3

#### 5 Analysis of 4 kb fragment

The 4 kb product obtained with NSE3/NSE-4 was excised from the gel and purified with glassmilk (Bresatec's Bresa Clean). As attempts at cloning the 4kb product were initially unsuccessful, alternative strategies were devised. The purified 4 kb  
10 product was digested with *Xba*I and two fragments of 1.3 kb and 0.9 kb (see Figure 2) were sub-cloned into the vector pGEM11 (Promega corporation, USA), which had been previously digested with *Xba*I giving the plasmids pGX1.3 and pGX0.9, respectively. The 4 kb fragment was also digested with *Sph*I and blunt-ended before cloning the digestion products into pGEM11 (previously digested with *Xba*I and blunt-ended). As a result, two *Sph*I fragments of 1.1 kb and 1.4 kb (see Figure  
15 2) were sub-cloned and the plasmids named pGS1.1 and pGS1.4, respectively. The 1.4 kb fragment did not show any *Sph*I recognition sequences in one of its ends, indicating that some exonuclease activity had taken place during the blunt-ending process.

20

### EXAMPLE 4

#### Reconstruction and sequencing of the 2.5kb pGEL-1 region

The sequencing strategy for pGEL-1 is shown in Figure 3. Sequencing was  
25 performed using the dideoxy chain termination method (Sanger et al, 1977) using a Applied Biosystems kit (Applied Biosystems, USA). Analysis of the sequences revealed that the four clones partially overlapped. The 1.3 kb *Xba*I and 1.1 kb *Sph*I fragments contained the 5' untranslated region of the *AIM-1* cDNA, confirming that this region is upstream of the *AIM-1* gene. As a result, a partial restriction map for  
30 a 2.5 kb region of the 4 kb DNA fragment was generated. The nucleotide sequence of pGEL-1 is shown in Figure 4 and in <400>3.

With this information in hand, the promoter region was reconstructed by the following strategy (refer to Figure 5). pGS1.4 was digested with *Hind*III and blunt ended. The promoter insert was then excised with *Spel*, obtaining a 1.4 kb fragment with blunt-*Spel* ends (see Figure 5(a)).

5

pGS1.1 was linearised with *Safl* and blunt ended. Later the linearised construct was digested with *Spel* resulting in a linearised vector with blunt-*Spel* ends containing the 3' end of the promoter region (Figure 5(b)). The fragment excised in (a) was ligated into (b) to reconstruct the 2.5 kb pGEL-1 promoter (Figure 5(b)).

10

#### EXAMPLE 5 Characterization of pGEL-1

##### **(a) Generation of deletion fragments and chimeric gene constructs**

15

To fully characterize pGEL-1, two different lengths of the promoter sequence were used: the entire 2.5 kb sequence and a 1.4 kb fragment upstream of the first ATG codon.  $\beta$ -Glucuronidase (*GUS*) and luciferase (*LUC*) reporter genes were each ligated to one or other of the promoter fragments and to the 3' terminator region 20 from the *Agrobacterium tumefaciens* nopaline synthase gene (NOS) to generate a series of chimeric gene constructs.

A series of 7 deletions in the promoter region were also generated, starting from 170 base-pairs upstream of the first ATG codon. Each of these was likewise 25 ligated to the NOS 3' terminator region and to the *GUS* reporter gene. Intermediate vectors containing each of the promoter fragments (0.17, 0.23, 0.45, 0.70, 0.88, 1.1, 1.4, 1.6 or 2.5 kb) ligated to the *GUS* reporter gene and NOS terminator were generated in pBluescript. Intermediate vectors comprising the promoter fragments 1.4 and 2.5 kb were also ligated to the *LUC* reporter gene with the NOS terminator. 30 For control purposes, additional constructs containing the cauliflower mosaic virus 35S promoter linked to either *GUS* or *LUC* were also prepared.

These chimeric constructs were then successfully ligated into the polylinker of the binary vector backbone pPZP111 (Hajdukiewicz *et al.*, 1994), for use in plant transformation. A range of these constructs, comprising pGEL-1 is shown in Figures 6A(i) to 6A(xii). The backbone vector pPZP111 is shown in Figure 6B. The bluescript vector comprising GUS and the NOS terminator (pGuNt) is shown in Figure 6C.

**(b) Transformation and regeneration of tobacco**

10 The characterization of pGEL-1 was carried out using tobacco as the model plant system. Tobacco transformation was carried out as described by Svab *et al.* (1995). Multiple independent transgenic lines were generated with each of the binary constructs.

15 (c) Generation of T2 lines

T2 lines were generated from selected T1 lines by self-pollination. Tissue of young transgenic tobacco lines, containing the pGEL-1:GUS gene construct, were histochemically assayed to visualise GUS activity. Very intense levels of  
20 histochemical stain indicate high levels of expression of the GUS gene in tissues of young plants (Figure 7A, B).

(d) Quantitative analysis of pGEL-1

25 To quantify levels of expression of the GUS gene under control of pGEL-1 and compare it to levels obtained using the CaMV35S promoter, quantitative analysis was carried out on two independent transgenic T2 tobacco lines (3-4 and 7-3) containing the pGEL-1:GUS genetic construct and one transgenic T2 line (5-2) containing the 35S:GUS genetic construct. Assays were performed according to  
30 the method of Jefferson (1987) on different plant tissues including root, stem, petiole and first, second and third true leaves. The results indicated that constructs

- 39 -

containing pGEL-1 drive levels of expression two to five times higher than that obtained using the 35S promoter (see Figures 8, 9, 10 and 11).

**(e) Deletion analysis**

5

Several deletions of the pGEL-1 promoter regions were made and fused to the GUS gene ranging from 1.027 bp to 86 bp. Figure 11 shows the GUS activity measures performed in several plant organs at different developmental stages. It is observed that there is a general decline in activity in the shorter promoter constructs in immature and mature leaf tissue. Nevertheless, the decrease in activity is not so evident in other tissues.

**EXAMPLE 6**  
**Transformation procedures**

15

The promoter is introduced into a range of plants generally from within a construct. Genetic material is introduced into the *Agrobacterium tumefaciens* strain AGL0 by adding 5 µg of plasmid DNA to 100 µl of competent AGL0 cells prepared by inoculating a 50 ml culture of MG/L (Garfinkel and Nester, 1980). These are cultured and grown for 16 hours with shaking at 28°C. The cells are then pelleted and resuspended in 0.5 ml of 85% v/v 100 mM CaCl<sub>2</sub>/15% v/v glycerol. The DNA-*Agrobacterium* mixture is frozen by incubation in liquid N<sub>2</sub> for 2 minutes and then allowed to thaw by incubation at 37°C for 5 minutes. The DNA/bacterial mix is then placed on ice for a further 10 minutes. The cells are then mixed with 1 ml of LB (Sambrook *et al*, 1989) media and incubated with shaking for 16 hours at 28°C. Cells of *A. tumefaciens* carrying genetic material are selected on LB agar plates containing 10 µg/ml gentamycin or other suitable selection such as another antibiotic or a herbicide. The presence of genetic material is confirmed by Southern analysis of DNA isolated from the gentamycin-resistant transformants or any other selectable molecule such as another antibiotic or a herbicide.

**Petunia transformations****(a) Plant material**

Leaf tissue from mature plants is treated in 1.25% w/v sodium hypochlorite for 2 minutes and then rinsed three times in sterile water. The leaf tissue is then cut into 25 mm<sup>2</sup> squares and precultured on MS media (Murashige and Skoog, 1962) supplemented with 0.05 mg/l kinetin and 1.0 mg/l 2,4-dichlorophenoxyacetic acid (2,4-D) for 24 hours.

**10 (b) Co-cultivation of *Agrobacterium* Tissue**

*Agrobacterium tumefaciens* strain AGL0 containing genetic material is maintained at 4°C on MG/L agar plates with 100 mg/l gentamycin. A single colony is grown overnight in liquid medium containing 1% w/v Bacto-peptone, 0.5% w/v Bacto-yeast extract and 1% w/v NaCl. A final concentration of 5 x 10<sup>8</sup> cells/ml is prepared the next day by dilution in liquid MS medium containing B5 vitamins (Gamborg et al, 1968) and 3% w/v sucrose (BPM). The leaf discs were dipped for 2 minutes into BPM containing AGL0/genetic material. The leaf discs are then blotted dry and placed on co-cultivation media for 4 days. The co-cultivation medium consists of SH medium (Schenk and Hildebrandt, 1972) supplemented with 0.05 mg/l kinetin and 1.0 mg/l 2,4-D and included a feeder layer of tobacco cell suspension spread over the co-cultivation medium with a filter paper placed on top of the tobacco cell suspension.

**(c) Recovery of transgenic plants**

25 After co-cultivation, the leaf discs are transferred to a selection medium (MS medium supplemented with 3% w/v sucrose, α-benzylaminopurine (BAP) 2 mg/l, 0.5 mg/l α-naphthalene acetic acid (NAA), kanamycin 300 mg/l, 350 mg/l cefotaxime and 0.3% w/v Gelrite Gellan Gum (Schweizerhall)). Regenerating explants are transferred to fresh selection medium after 4 weeks. Adventitious 30 shoots which survive the kanamycin selection are isolated and transferred to BPM containing 100 mg/l kanamycin and 200 mg/l cefotaxime for root induction. All

- 41 -

cultures are maintained under a 16 hour photoperiod ( $60 \mu\text{mol. m}^{-2} \text{ s}^{-1}$  cool white fluorescent light) at  $23 \pm 2^\circ\text{C}$ . When roots reach 2-3 cm in length the transgenic petunia plantlets are transferred to autoclaved Debco 51410/2 potting mix in 8 cm tubes. After 4 weeks, plants are replanted into 15 cm pots, using the same potting mix, and maintained at  $23^\circ\text{C}$  under a 14 hour photoperiod ( $300 \mu\text{mol. m}^{-2} \text{ s}^{-1}$  mercury halide light).

### EXAMPLE 7

#### Transformation of *Dianthus caryophyllus*

##### 10 a. Plant material

*Dianthus caryophyllus*, (cv. Crowley Sim, Red Sim, Laguna) cuttings are used in this experiment. The outer leaves are removed and the cuttings are sterilized briefly in 70% v/v ethanol followed by 1.25% w/v sodium hypochlorite (with Tween 20) for 6 minutes and rinsed three times with sterile water. All the visible leaves and axillary buds are removed under the dissecting microscope before co-cultivation.

##### b. Co-cultivation of *Agrobacterium* and *Dianthus* tissue

*Agrobacterium tumefaciens* strain AGL0 containing a genetic construct encoding a cytochrome P450 monooxygenase and optionally an associated protein as herein described is maintained at  $4^\circ\text{C}$  on MG/L(Garfinkel and Nester, 1980) agar plates with 100 mg/l gentamycin. A single colony is grown overnight in liquid MG/L broth and diluted to  $5 \times 10^8$  cells/ml the next day before inoculation. *Dianthus* tissue is co-cultivated with *Agrobacterium* on MS medium (Murashige and Skoog, 1962) supplemented with 3% w/v sucrose, 5 mg/l  $\alpha$ -naphthalene acetic acid (NAA), 20  $\mu\text{M}$  acetosyringone and 0.8% w/v Difco Bacto Agar (pH 5.7).

##### c. Recovery of transgenic *Dianthus* plants

Co-cultivated tissue is transferred to MS medium supplemented with 1 mg/l benzylaminopurine (BAP), 0.1 mg/l NAA, 150 mg/l kanamycin, 500 mg/l ticarcillin and 0.8% w/v Difco Bacto Agar (selection medium). After three weeks, explants

- 42 -

are transferred to fresh selection medium and care is taken at this stage to remove axillary shoots from stem explants. After 6-8 weeks on selection medium, healthy adventitious shoots are transferred to hormone free MS medium containing 3% w/v sucrose, 150 mg/l kanamycin, 500 mg/l ticarcillin, 0.8% w/v Difco Bacto Agar. At 5 this stage, GUS histochemical assay (Jefferson, 1987) and/or NPT II dot-blot assay (McDonnell et al, 1987) are used to identify transgenic shoots. Transgenic shoots are transferred to MS medium supplemented with 3% w/v sucrose, 500 mg/l ticarcillin and 0.4% w/v Gelrite Gellan Gum (Schweizerhall) for root induction. All cultures are maintained under a 16 hour photoperiod (120  $\mu$ E cool white fluorescent 10 light) at 23 $\pm$  2°C. When plants are rooted and reached 4-6 cm tall they are acclimatised under mist. A mix containing a high ratio of perlite (75% or greater) soaked in hydroponic mix (Kandreck and Black, 1984) is used for acclimation, which typically lasts 4-5 weeks. Plants are acclimated at 23°C under a 14 hour photoperiod (200  $\mu$ E mercury halide light).

15

#### EXAMPLE 8

##### **Transformation of *Rosa hybrida***

###### **1. *Rosa hybrida* cv Royalty**

20 Plant tissues of the rose cultivar Royalty are transformed according to the method disclosed in PCT/AU91/04412, having publication number WO92/00371.

###### **2. *Rosa hybrida* cv Kardinal**

###### **a. Plant material**

25 Kardinal shoots are used. Leaves are removed and the remaining shoots (5-6 cm) are sterilized in 1.25 % w/v sodium hypochlorite (with Tween 20) for 5 minutes followed by three rinses with sterile water. Isolated shoot tips are soaked in sterile water for 1 hour and precultured for 2 days on MS medium containing 3% w/v sucrose, 0.1 mg/l BAP, 0.1 mg/l kinetin, 0.2 mg/l Gibberellic acid, 0.5% w/v 30 polyvinyl pyrrolidone and 0.25% w/v Gelrite Gellan Gum, before co-cultivation.

b. **Co-cultivation of *Agrobacterium* and *Rosa* shoot tissue**

*Agrobacterium tumefaciens* strains ICMP 8317 (Janssen and Gardner, 1989) and AGL0, containing genetic constructs comprising pGEL-1 and optionally a structural gene operably linked thereto are maintained at 4°C on MG/L agar plates with 100 mg/l gentamycin. A single colony from each *Agrobacterium* strain is grown overnight in liquid MG/L broth. A final concentration of  $5 \times 10^8$  cells/ml is prepared the next day by dilution in liquid MG/L. Before inoculation, the two *Agrobacterium* cultures are mixed in a ratio of 10:1. A longitudinal cut is made through the shoot tip and an aliquot of 2  $\mu$ l of the mixed *Agrobacterium* cultures is placed as a drop 10 on the shoot tip. The shoot tips are co-cultivated for 5 days on the same medium used for preculture.

*Agrobacterium tumefaciens* strain AGL0 is maintained at 4°C on MG/L agar plates with 100 mg/l kanamycin. A single colony from each *Agrobacterium* strain is grown 15 overnight in liquid MG/L broth. A final concentration of  $5 \times 10^8$  cells/ml is prepared the next day by dilution in liquid MG/L.

c. **Recovery of transgenic *Rosa* plants**

After co-cultivation, the shoot tips are transferred to selection medium. Shoot tips 20 are transferred to fresh selection medium every 3-4 weeks. Galls observed on the shoot tips are excised when they reached 6-8 mm in diameter. Isolated galls are transferred to MS medium containing 3% w/v sucrose, 25 mg/l kanamycin, 250 mg/l cefotaxime and 0.25% w/v Gelrite Gellan Gum for shoot formation. Shoots regenerated from gall tissue are isolated and transferred to selection medium. 25 GUS histochemical assay and callus assay are used to identify transgenic shoots. Transgenic shoots are transferred to MS medium containing 3% w/v sucrose, 200 mg/l cefotaxime and 0.25% w/v Gelrite Gellan Gum for root induction. All cultures are maintained under 16 hour photoperiod (60  $\mu$ E cool white fluorescent light) at 23± 2°C. When the root system is well developed and the shoot reached 5-7 cm in 30 length the transgenic rose plants are transferred to autoclaved Debco 514110/2 potting mix in 8 cm tubes. After 2-3 weeks plants are replanted into 15 cm pots

- 44 -

using the same potting mix and maintained at 23°C under a 14 hour photoperiod (300 µE mercury halide light). After 1-2 weeks potted plants are moved to glasshouse (Day/Night temperature : 25-28°C/14°C) and grown to flowering.

5

### EXAMPLE 9

#### Transformation of *Chrysanthemum morifolium*

##### a. Plant material

*Chrysanthemum morifolium* (cv. Blue Ridge, Pennine Chorus) cuttings are obtained. Leaves are removed from the cuttings, which are then sterilized briefly in 10 70% v/v ethanol followed by 1.25% w/v sodium hypochlorite (with Tween 20) for 3 minutes and rinsed three times with sterile water. Internodal stem sections are used for co-cultivation.

15 b. Co-cultivation of *Agrobacterium* and *Chrysanthemum* tissue

*Agrobacterium tumefaciens* strain LBA4404 (Hoekema et al, 1983), containing a genetic construct of the present invention is grown on MG/L agar plates containing 50 mg/l rifampicin and 10 mg/l gentamycin. A single colony from the *Agrobacterium* is grown overnight in the same liquid medium. These liquid cultures are made 10% 20 v/v with glycerol and 1 ml aliquots transferred to the freezer (-80°C). A 100-200µl aliquot of each frozen *Agrobacterium* is grown overnight in liquid MG/L containing 50 mg/l rifampicin and 10 mg/l gentamycin. A final concentration of  $5 \times 10^8$  cells/ml is prepared the next day by dilution in liquid MS containing 3% w/v sucrose. Stem sections are co-cultivated with *Agrobacterium* in co-cultivation medium for 4 days.

25

##### c. Recovery of transgenic *Chrysanthemum* plants

After co-cultivation, the stem sections are transferred to selection medium. After 3-4 weeks, regenerating explants are transferred to fresh medium. Adventitious shoots which survive the kanamycin selection are isolated and transferred to MS 30 medium containing kanamycin and cefotaxime for shoot elongation and root induction. All cultures are maintained under a 16 hour photoperiod (80 µE cool

- 45 -

white fluorescent light) at 23 ± 2°C. Leaf samples are collected from plants which rooted on kanamycin and Southern blot analysis is used to identify transgenic plants. When transgenic chrysanthemum plants reach 4-5 cm in length, they are transferred to autoclaved Debco 51410/2 potting mix in 8 cm tubes. After 2 weeks, 5 plants are replanted into 15 cm pots using the same potting mix and maintained at 23°C under a 14 hour photoperiod (300 µE mercury halide light). After 2 weeks potted plants are moved to glasshouse (Day/Night temperature : 25-28°C/14°C) and grown to flowering.

10

#### EXAMPLE 10

##### **Bombardment of plant tissue with genetic material comprising pGEL-1 operably linked to a gene of interest**

The aim of these experiments is to introduce genetic constructs comprising pGEL-1 15 into plant tissue such as petals and then to screen for at least transient expression.

The gene bombardment protocol is initially optimised using the reporter vector pGEL-1:GUS. GUS expression is assayed using the method described by Jefferson et al (1992). Efficiency of the transformation is measured by the mean number of 20 blue spots per petal bombardment. The parameters examined during these initial optimisation experiments are target distance, bombardment pressure and petal developmental stage.

Plasmid DNA is obtained from *E.coli* using a standard alkaline lysis procedure with 25 and without additional procedures for purification of the resultant DNA (Sambrook et al, 1989). The DNA is prepared for bombardment by combining various amounts of tungsten particle solution with DNA. After vortexing, the particles are precipitated with CaCl<sub>2</sub> and spermidine. After removing a portion of the supernatant, the tungsten suspension was vortexed and an aliquot removed for bombardment.

30

In this experiment, white petunia flowers are used for bombardment. Petunia plants

- 46 -

having other colours may also be used. The device used for bombardment is the particle inflow gun developed by Finer *et al* (1992) which propels tungsten particles directly in a stream of helium towards the target. The petal is placed in a petri dish containing filterpaper moistened with appropriate medium. Each petal preparation is

5 bombarded with one of:

- a) vector containing pGEL-1 alone; or
- b) vector containing pGEL-1 operably linked to GUS (or other gene of interest);
- c) vector containing a GUS control (or other gene of interest).

10

In some cases, the vector containing the GUS control is bombarded simultaneously with either or both types of vectors containing pGEL-1.

The optimum petal distance and helium pressure found during these experiments is  
15 12.5 cm shelf height and 1000 Kpa, respectively. Optimum DNA is about 2-5 ng  
DNA/petal. A negative control containing tungsten particles only is also included.

The success of the bombardment is analysed by the presence of blue spots after  
overnight incubation of the bombarded petal in the presence of GUS substrate.

20

#### **EXAMPLE 11**

##### **Optimization of microprojectile bombardment of "Sunrise Solo" somatic embryos**

25 A gene gun (based on the particle inflow gun; Finer *et al*, 1992) is used for  
bombardment. Tungsten particles (0.7  $\mu$ m, Biorad) are used as microprojectiles;  
16-20 mg tungsten is washed with ethanol and then washed three times with sterile  
double distilled water (ddH<sub>2</sub>O) before suspension in 200  $\mu$ l double distilled water.  
For preparation of microprojectiles, 100  $\mu$ g/l tungsten suspension is mixed with 1  
30  $\mu$ g/l plasmid DNA, 2.5 mM CaCl<sub>2</sub> and 100 mM spermidine-free base. The plasmid

- 47 -

DNA used is, for example, p2.5GuNt (pGEL-1 promoter::GUS gene::Nos Terminator in a pBluescript backbone). However, any pGEL-1 construct may be used. For example, GUS may, of course, be replaced by a gene of interest. All solutions are kept on ice. The suspension is thoroughly mixed, then allowed to

5 settle on ice for 5 minutes before 100  $\mu$ l of the supernatant is removed and discarded. The remaining suspension is raked several times on the rack immediately before using 4  $\mu$ l of the mixture for each bombardment. A protective baffle of nylon mesh (Franks and Birch, 1991) is placed over the tissue during bombardment. The tissues are bombarded using various pressures and distances.

10 The bombarded embryos are then transferred onto a half-strength MS medium and incubated for 48 hours. After this period glucuronidase (GUS) activity is assayed histochemically by incubating the embryos in 8-bromo-4-chloro-3-indolyl glucuronide (X-gluc) solution overnight at 37°C (Jefferson, 1987). Transient expression is assayed 12 hours after incubation and measured as total blue foci

15 count per shot area.

In experiment one, somatic embryos are placed on osmoticum medium (half strength MS salts and vitamins, 0.2 M mannitol and 0.5% w/v phytagel) for a total of six hours (three hours before and after bombardment). A protective baffle of nylon

20 mesh (Franks and Birch, 1991) is placed over the tissue during bombardment. The tissues are bombarded using four different pressures (1000, 1500, 1800 and 2000 kPa). The distance of the target tissue from the filter unit containing the microprojectiles is 17.5 cm. The bombarded embryos are then transferred on a half-strength MS medium and incubated for 48 hours. After this period, GUS activity

25 is assayed histochemically by incubating the embryos in 5-bromo-4-chloro-3-indolyl glucuronide (X-gluc) solution overnight at 37°C (Jefferson, 1987). Transient expression is assessed as total blue foci count per shot area.

In a second experiment, the somatic embryos produced from immature fruits are

30 transferred onto a sterile filter paper (overlaid onto the medium) and are spread firmly over the surface of the filter paper with a sterile metal spatula in order to

- 48 -

squash the embryos (Gonsalves *et al*, 1997). The embryogenic cells are allowed to proliferate for another four to six weeks and are re-spread over the filter paper and, bombarded three days later as described above.

5 Three distances of the target somatic embryos from the filter containing the microprojectiles are tested. These distances are 17.5, 15.0 and 12.5 cm, and the pressure is 1000 kPa. The target tissues are bombarded following the procedure previously described.

10

## EXAMPLE 12

### Papaya transformation

Papaya tissue is transformed with genetic material using the following protocol. Growing temperatures are at 22-35°C.

15

#### 1. Somatic Embryo Induction

Embryos are cut from immature (90 days old) papaya seeds and cultured on somatic embryo induction medium (SEIM) for 4-6 weeks or 3-4 months. The 20 embryos are sub-cultured every 2 weeks on fresh SEIM. Seven to 12 embryos are then squashed using a metal spatula on 3MM filter paper, 3 days before shooting on SEIM.

#### 2. Shooting

25

Embryos are placed, while still on the filter paper, onto osmoticum medium (OSM). Conveniently, this is done in the morning. The embryos are maintained on OSM for at least 8 hours before, during and after shooting.

30 a) Conditions for shooting are as follows:

Pressure: 1000 KPa

- 49 -

Distance target to filter: 12.5 cm

Pulse time: 50 msec

b) Tungsten Particles (0.7 µm): Particles are washed in ethanol 3 times, then 3 times in sterile double distilled H<sub>2</sub>O (ddH<sub>2</sub>O) and then resuspended to a final concentration of 100 µg/µl in ddH<sub>2</sub>O.

c) DNA preparation:

The following components are added together:

10 50 µl Tungstein (100 µg/µl)  
20 µl DNA (500 - 1000 ng total) [pPZP2.5GuNt or other suitable construct]  
50 µl CaCl<sub>2</sub> (2.5 mM)  
20 µl Spermidine (100 mM)

15 The latter two components are added in quick succession.

The mixture is allowed to sit for 5 min, for the tungsten to collect on the bottom and approximately 110 µl is removed from the top and discarded. This gives enough for 5 shots. Shots are made as quickly as possible because the DNA dissociates from 20 tungsten.

d) Shooting:

Prior to shooting, the gun is swabbed together with the bench with alcohol.

25 Tungsten-DNA is thoroughly resuspended and 4 µl is pipetted into the filter units Working aseptically, the baffle is placed onto the medium containing the tissue and slightly pressed into the agar. The filter is then screened into the gun. The gun chamber is evacuated until the vacuum gauge approximately reads -29mmHg and the fire button is pressed. The vacuum is immediately released and the tissue  
30 removed.

- 50 -

**3. Recovery**

Embryos are placed, still on the filter paper onto recovery medium (RM) after shooting for 5 - 7 days.

5

**4. Pre-selection**

Embryos are removed from the filter paper and placed onto PSM for 1 month and sub-cultured every 2 weeks.

10

**5. Full Selection**

All embryos are placed onto a full selection medium (FSM) and sub-culture every 2-3 weeks. Tissue which is growing well is placed onto to FSM with 300 mg/l.

15 kanamycin for two sub-cultures. Surviving tissue is placed onto EGM.

**6. Regeneration**

a) Embryo germination.

20

Embryos are placed onto embryo germination medium (EGM) with 150 mg/l kanamycin for 3-4 months (or longer until germinating clumps emerge). The embryos are sub-cultured every 2-4 weeks and maintained until green tissue emerges (1-2mm).

25

b) Single shoot growing.

Green tissue is placed onto full strength single shoot growing medium (SSGM) until a whole plant is obtained. Tissue is sub-cultured every month.

30

- 51 -

**7. Micropropagation**

**a) Shoot multiplication.**

5 Stems are cut and leaves and roots removed and placed onto shoot multiplication medium (SMM) for 2 weeks up to one month.

**b) Root Induction.**

10 New emerging shoots are cut from the central shoot and placed onto root induction medium (RIM) for 3 days.

c) Shoots are placed onto full strength SSGM and sub-cultured every month until formation of a full grown plant.

15

d) The plant can be kept longer (up to one year) in culture using a minimal growth medium containing full strength SSGM plus 1% w/v fructose instead of glucose.

**20 8. Potting out**

The plants are planted out into Styrofoam seedling trays using steam sterilised soil.

After 3 days, the seedling trays are drenched with a fungicide (eg. Dithane M45 or Alliette). These plants are placed in a humidifying chamber with the following

25 acclimatisation conditions:

1st week 90-100% humidity

2nd week 70% humidity

3rd week 60% humidity

30 4th week open door a bit

- 52 -

The plants are left in the chamber until the leaves become shiny. Plants are gently watered with distilled water when needed.

The following media are used:

5

**1. Somatic embryo induction media (SEIM)**

		1 litre
	1/2 strength MS salts	2.17 g
	MS Vitamins	1 ml (1000x stock)
10	2,4-D	10 ml (1 mg/ml stock)
	Glutamine	20 ml (5 mg/ml stock)
	Myo inositol	10 ml (1mg/ml stock)
	thiamine HCl	10 ml (1 mg/ml stock)
	Sucrose	30 g
15	Agar	8 g
	or Phytigel	5 g
	pH 6.5 - 7	
	MS Vitamins(1000x):	100 ml
20	Stored frozen	
	Thiamine-HCl	10 mg
	Pyridoxine-HCl	50 mg
	Nicotinic acid	50 mg
	Glycine	200 mg
25	Myo-inositol	10 g

**2. Osmoticum media (OSM)**

		1 litre
	1/2 strength MS salts	2.17 g
30	1/2 MS Vitamins	500 µl (1000x stock)
	Mannitol	36.4 g

- 53 -

Agar 8 g  
or Phytigel 5 g  
pH 6.5 - 7

5

**3. Recovery media (RM)**

1 litre  
1/2 strength MS salts 2.17 g  
1/2 MS Vitamins 500 µl (1000x stock)  
10 Sucrose 30 g  
Agar 8 g  
or Phytigel 5 g  
pH 6.5 - 7

15 **4. Pre-selection (PSM)**

SEIM with 75 mg/l kanamycin (750 µl of a 100 mg/ml stock in 1 litre)

20 **5. Full selection media (FSM)**

SEIM with 150 mg/l kanamycin (1500 µl of a 100 mg/ml stock in 1 litre) or  
300 mg/ml kanamycin (3000 µl of a 100 mg/ml stock in 1 litre)

25 **7. Embryo germination media (EGM)**

1 litre  
1/2 Strength MS salts 2.17 g  
1/2 MS Vitamins 500 µl (1000x stock)  
Kinetin 0.25 µM (2.5 ml of a 100 µM stock)  
IAA 4.5 µM (45 ml of a 100 µM stock)  
30 GA3 0.8µM (8 ml of a 100 µM stock, filter sterilised,  
added after autoclaving)

PCT/AU99/00705

- 54 -

Sucrose                    30 g  
Agar                      8 g  
or Phytigel              5 g  
pH 6.5 - 7

5

After autoclaving add 1500 µl of a 100 mg/ml stock in 1 litre

**8. Single shoot growing media (SSGM)**

10        Full strength SSGM                    1 litre  
            De Fossard's Minerals                80 ml (1X)  
            De Fossard's Vitamins                50 ml (2X)  
            Sucrose                                30 g  
            Agar                                    8 g  
15        or Phytigel                            5 g  
            pH 6.5 - 7

**9. Shoot multiplication media (SMM)**

20        1 litre  
            De Fossard's Minerals                80 ml (1X)  
            De Fossard's Vitamins                50 ml (2X)  
            Sucrose                                30 g  
            0.25µM BAP                            2.5 ml of a 100 µM stock  
            0.25µM NAA                            250 µl of a 1000 µM stock  
25        Agar                                    8 g  
            or Phytigel                            5 g  
            pH 6.5 - 7

**10. Root induction media (RIM)**

30        1 litre

- 55 -

	De Fossard's Minerals	40 ml (1X)
	De Fossard's Vitamins*	50 ml (1X)
	Sucrose	30 g
	10 µM IBA	10 ml of a 1000 µM stock
5	Agar	8 g
	or Phytigel	5 g
	pH 6.5 - 7	

\*De Fossards vitamins with no riboflavin

10	De Fossards Minerals (1X)	2.4 litre
	NH <sub>4</sub> NO <sub>3</sub>	300 ml
	KNO <sub>3</sub>	600 ml
	NaH <sub>2</sub> PO <sub>4</sub> .H <sub>2</sub> O	300 ml
15	CaCl <sub>2</sub>	300 ml
	(Ferric sodium salt) FeNaEDTA	300 ml
	MgSO <sub>4</sub> .7H <sub>2</sub> O	300 ml
	Micronutrients	300 ml
20	Vitamins #6 (2X)	2 litre
	Inositol	4.32 g
	Nicotinic acids	196 mg
	Pyridoxine HCl (100 mg/ml)	496 µl
	Thiamine HCl	539 mg
25	Biotin (50 mg/ml)	200 µl
	Folic acid (50 mg/ml)	712 µl
	Ca-Pantothenate (50 mg/ml)	1910 µl
	Riboflavin	150.8 mg
	Ascorbic acid (100 mg/ml)	704 µl
30	Choline chloride (100 mg/ml)	560 µl
	Glycine (100 mg/ml)	1504 µl

- 56 -

	L-Cysteine HCl	756 mg
	Stock Solutions	g/litre
	NH <sub>4</sub> NO <sub>3</sub>	160.1 (2 M)
5	KNO <sub>3</sub>	101.11 (1 M)
	NaH <sub>2</sub> PO <sub>4</sub> .H <sub>2</sub> O	31.202 (0.23 M)
	CaCl <sub>2</sub>	59.46 (0.54 M)
	(Ferric sodium salt)	
	FeNaEDTA	3.67 (0.01 M)
10	MgSO <sub>4</sub> .7H <sub>2</sub> O	73.95 (0.3 M)
	Micronutrients	1 litre
	H <sub>3</sub> Bo <sub>3</sub>	0.9276 (0.015 M)
	MnSO <sub>4</sub> .4H <sub>2</sub> O	2.2306 (0.01 M)
15	ZnSO <sub>4</sub> .47H <sub>2</sub> O	1.1502 (4 x 10 <sup>-3</sup> M)
	CuSO <sub>4</sub> .5H <sub>2</sub> O	0.0374 (1.5 x 10 <sup>-4</sup> M)
	Ammonium Molybdate	
	(NH <sub>4</sub> ) <sub>6</sub> Mo <sub>7</sub> O <sub>24</sub> .4H <sub>2</sub> O	0.1236 (1 x 10 <sup>-4</sup> M)
	CoCl <sub>2</sub> .4H <sub>2</sub> O	0.0238 (1 x 10 <sup>-4</sup> M)
20	KCl	0.0830 (5 x 10 <sup>-4</sup> M)
	Vitamin Stocks	
	Pyridoxine HCl (100 mg/ml)	1.5 g/15 ml in H <sub>2</sub> O/ETOH
	Biotin (50 mg/ml)	750 mg/15 ml dil HCl
25	Folic acid (50 mg/ml)	750 mg/15 ml dil NaOH
	Ca-Pantothenate (50 mg/ml)	750 ml/15 ml H <sub>2</sub> O
	Ascorbic acid (100 mg/ml)	1.5 g/15 ml H <sub>2</sub> O
	Choline chloride (100 mg/ml)	1.5 g/15 ml H <sub>2</sub> O
	Glycine (100 mg/ml)	1.5 g/15 ml H <sub>2</sub> O
30	De Fossard media (full strength) contains (in 1 litre)	

- 57 -

	NH <sub>4</sub> NO <sub>3</sub>	10 ml
	KNO <sub>3</sub>	20 ml
	NaH <sub>2</sub> PO <sub>4</sub> .H <sub>2</sub> O	10 ml
	CaCl <sub>2</sub>	10 ml
5	FeNaEDTA	10 ml
	MgSO <sub>4</sub> .7H <sub>2</sub> O	10 ml
	Miconutrients	10 ml
	Vitamins #6 (1X)	100 ml (50 ml of 2X)

10

#### EXAMPLE 13

##### Transformation of cotton, *Brassica* and maize

Genetic constructs comprising pGEL-1 or a functional derivative or homologue thereof operably linked to a gene of interest, such as, for example, a reporter gene, 15 are introduced into cotton; *Brassica* (e.g. canola) and maize. Cotton is transformed using *Agrobacterium* using the method described in US Patent No. 5, 004, 863. *Brassica* sp are transferred using *Agrobacterium* using the method described in US Patent No. 5, 188, 958. Maize is transformed via immature embryos using the method described in US Patent No. 5, 641, 664. These plants may also be 20 transformed using electroporation, biolistic procedures and polyethylene glycol amongst other methods.

#### EXAMPLE 14

##### Transformation of wheat, barley and rice

25

Wheat transformation was by the method of Karunaratne *et al* (1996) with slight modifications.

##### Target tissue

30

Young caryopsis are dissected from spikes of *Triticum aestivum* L. cv. Hartog,

- 58 -

approximately 12 to 14 days post anthesis and surface sterilised with 10% w/v Dairy-Chlor (100 g/l available chlorine). Immature embryos are isolated and cultured in dark on MS medium (Murashige and Skoog, 1962) supplemented with 2, 4-dichlorophenoxyacetic acid (10  $\mu$ M). After 7 days of culture, the immature  
5 embryos are subjected to particle bombardment.

#### **Microparticle bombardment**

The genetic construct to be introduced into plant cells is precipitated onto tungsten  
10 particles (1.2  $\mu$ m) as described by Finer and McMullen (1990) with the following  
modifications. An aliquot of 25  $\mu$ l of a 500 mg/ml suspension of tungsten particles  
(1.2  $\mu$ m) in distilled water is taken in an eppendorf tube followed by stepwise  
addition of the following: 5  $\mu$ l of plasmid DNA (5  $\mu$ g), 25  $\mu$ l of calcium chloride (2.5  
M), 10  $\mu$ l of spermidine (0.1 M). The contents in the tube is mixed by finger  
15 vortexing and kept on ice. After 5 min, 30  $\mu$ l of the supernatant is discarded and  
300  $\mu$ l of ethanol (90%) is added and kept on ice after mixing the contents. After 1  
min, the tube is centrifuged and all the supernatant discarded. The ethanol wash is  
repeated once and the DNA-coated tungsten is finally suspended in 30  $\mu$ l of  
ethanol (90%). The DNA-coated tungsten particles (2  $\mu$ l) are delivered to the target  
20 tissue using a particle inflow gun (Finer et al, 1992). The target tissue is placed on  
a shelf 14 cm from the screen of the filter holder, which carried a suspension of  
plasmid-DNA coated tungsten particles. After bombardment, the tissue is  
transferred to the original medium and cultured in the dark for 2 months with  
fortnightly subculture.

- 59 -

### **Plant regeneration and selection**

Embryogenesis leading to plant regeneration is stimulated by transferring clumps of embryogenic callus to MS medium devoid of hormones and containing

5 Phosphinotricin (PPT) at a concentration of 5 mg/l. After two weeks, PPT-resistant plants and callus is transferred to fresh medium and subcultured weekly. PPT-resistant plants which are 4-5 cm are transferred to soil and kept under water mist for two weeks. Plants are then transferred to larger pots and kept in the glasshouse under day and night temperature of 22°C and 19°C, respectively.

10

Rice is transformed by the method of Abedinia *et al* (1997). Barley is transformed according to the method of Tingay *et al* (1997).

PCT/AU99/00705

- 60 -

<b>Hormone stocks</b>			
<b>Hormone</b>	<b>Molecular Weight (g)</b>	<b>mg/l Stock</b>	<b>Concentration of stock</b>
BAP	225.2	22.6	100 µM
NAA	186.2	186.2	1000 µM
5 IAA	175.2	17.5	100 µM
	346.4	34.6	100 µM
	215.2	21.5	100 µM
	203.23	203.2	1000 µM

- 61 -

**EXAMPLE 15**  
**Southern analysis of Transgenic T2 tobacco lines**

Genomic DNA (10 µg) was digested with *Eco*RI or *Bam*HI restriction enzymes; 5 separated in an electrophoresis gel and transferred to a Hybond™ (Amersham) Nylon membrane. The membrane was prehybridized and hybridized at high stringency following standard procedures (Sambrook *et al*, 1989). A DNA fragment containing the full GUS gene and Nos terminator was labelled with <sup>32</sup>P and used as a probe. After washing at high stringency the following results were observed:

10

- a) The *Eco*RI lanes of lines 3-4, 7-3 and 10-3 show a single fragment of the expected 4.5kb size indicating the intactness of the GEL-1:GUS:NosT construct in each of these lines.
- 15 b) The *Bam*HI lanes of lines 3-4, 7-3 and 10-3 show single fragments of different sizes (one fragment per line) indicating the existence of a single copy of GUS:NosT construct in each of these lines.
- c) The *Bam*HI lane of line 5-2 shows two bands indicating that this line contains 20 two copies of the CaMV 35S:GUS:NosT portion of the construct.

These results are shown in Figure 13

Those skilled in the art will appreciate that the invention described herein is 25 susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or 30 features.

- 62 -

Bibliography

Abedinia et al. *Aust. J. Plant Physiol.* 24: 133-141, 1977.

Ausubel et al. In. *Current Protocols in Molecular Biology*. 1987. Wiley Interscience (ISBN 047 150338)

Botella et al. *Plant Mol. Biol.* 20:425-436, 1992.

Botella et al. *Proc. Natl. Acad. Sci. USA* 92:1595-1598, 1995.

Franks and Birch. *Aust. J. Plant Physiol.* 18: 471-480, 1991

Frier and McMullen. *Plant Cell Report*. 8: 586-589, 1990.

Frier et al. *Plant Cell Reports*. 11: 323-328, 1992.

Gambourg et al. *Experimental Cell Research*, 50: 151-158, 1968.

Garfinkel and Nester. *Journal of Bacteriology* 144: 732-743, 1980.

Gonsalves et al. International Symposium on Biotechnology of Tropical and Subtropical Species, 29 September - 3 October, 1997, Brisbane, Australia, p. 71.

Hajdukiewicz et al. *Plant Mol. Biol.* 25:989-994, 1994.

Hoekema et al. *Nature* 303: 179-180, 1983.

Jannsen and Gerdner. *Plant Molecular Biology* 14: 61-72, 1989.

- 63 -

Jefferson. *Plant. Mol. Biol. Reporter* 5(4): 387-405, 1987.

Jefferson. *Plant. Mol. Biol. Reporter* 23: 429-435, 1996.

Karunaratne et al. *Aust. J. Plant. Physiol.* 23: 429-435, 1996.

McDonnell et al. *Plant Molecular Biology Reports* 4: 380-386, 1987.

Magdalita et al. *Aust. J. Bot.* 44: 343-353, 1996.

Murashige and Skoog. *Plant Physiology* 15: 73-97, 1962.

Needleman and Wunsch *J. Mol. Biol.* 48: 443-453, 1970.

Sambrook et al. *Molecular Cloning: A Laboratory Manual* Cold Spring Harbor Laboratories, Cold Spring Harbor, New York, USA, 1989.

Sanger et al. *Proc. Natl. Acad. Sci. USA* 74: 5463-5467, 1977.

Selker et al. *Dev. Biol.* 153:29-43, 1992.

Schenk and Hildebrandt. *Canadian Journal of Botany* 50: 199-204, 1972.

Svab et al. "Methods in Plant Molecule Biology: A Laboratory Course Manual" pp55-77, Cold Spring Harbor Laboratory Press, NY, 1995.

Tingay et al. *Plant Journal.* 11: 1369-1376, 1992.

**CLAIMS:**

1. An isolated nucleic acid molecule comprising a sequence of nucleotides or complementary sequence of nucleotides defining a promoter or a derivative or homologue thereof, wherein, in its native form, the promoter is inducible in response to physical stimulation.
2. An isolated nucleic acid molecule according to claim 1 wherein, in its native form, the promoter directs expression of a gene associated with ethylene production.
3. An isolated nucleic acid molecule according to claim 2 wherein the promoter, in its native form, directs expression of a gene encoding 1-aminocyclopropane-1-carboxylic acid (ACC) synthase.
4. An isolated nucleic acid molecule according to any one of claims 1 to 3 wherein the promoter is selected from the group consisting of:
  - (i) a promoter which directs expression of a nucleotide sequence as substantially set forth in <400>1;
  - (ii) a promoter which directs expression of a nucleotide sequence which hybridizes under low stringency conditions to <400>1;
  - (iii) a promoter which directs expression of a nucleotide sequence having at least about 50% similarity to <400>1;
  - (iv) a promoter which directs expression of a nucleotide sequence which encodes an amino acid sequence substantially as set forth in <400>2;
  - (v) a promoter which directs expression of a nucleotide sequence which

encodes an amino acid sequence which has at least about 60% similarity to <400>2.

5. An isolated nucleic acid molecule according to any one of claims 1 to 4 comprising a nucleotide sequence substantially as set forth in <400>3 or a nucleotide sequence having at least 25% similarity thereto or a nucleotide sequence capable of hybridising to <400>3 under low stringency conditions.
6. An isolated nucleic acid molecule comprising a sequence of nucleotides or complementary sequence of nucleotides defining a promoter or a derivative or homologue thereof, wherein, in its native form, the promoter is inducible in response to physical stimulation and wherein the promoter is selected from the list consisting of:
  - (i) a promoter which, in its native form, directs expression of a nucleotide sequence substantially as set forth in <400>1;
  - (ii) a promoter which, in its native form, directs expression of a nucleotide sequence which hybridizes under low stringency conditions to <400>1;
  - (iii) a promoter which, in its native form, directs expression of a nucleotide sequence having at least about 50% similarity to <400>1;
  - (iv) a promoter which, in its native form, directs expression of a nucleotide sequence which encodes an amino acid sequence substantially as set forth in <400>2;
  - (v) a promoter which, in its native form, directs expression of a nucleotide sequence which encodes an amino acid sequence which has at least about 60% similarity to <400>2;

(vi) a promoter comprising a nucleotide sequence substantially as set forth in <400>3;

(vii) a promoter comprising a nucleotide sequence capable of hybridizing to <400>3 under low stringency conditions; and

(viii) a promoter comprising a nucleotide sequence having at least about 25% similarity to <400>3.

7. A nucleic acid molecule defining a promoter or a homologue or derivative thereof said nucleic acid molecule obtainable by the method of isolating genomic DNA from plant cells, rendering the genomic DNA or portion thereof single stranded and then identifying a region on genomic DNA which hybridizes to a primer corresponding to all or part of <400>1 or a complementary form thereof and the cloning DNA upstream of the region of primer hybridization.

8. A nucleic acid according to claim 7 alternatively comprising amplifying regions of single stranded genomic DNA with a primer corresponding to all or part of <400>1 or a complementary form thereof and then cloning DNA upstream of the amplified region.

9. An isolated promoter obtainable by the method of:

(i) amplifying a region of single stranded plant genomic DNA with the primers <400> 4 and <400>5;

(ii) optionally amplifying the amplified DNA of (i) above with primers selected from <400> 6 and <400>7 or <400> 8 and <400>9;

(iii) running amplified DNA on a gel and excising the product of amplification; and

(iv)- subcloning product and identifying the promoter.

10. A nucleic acid according to claim 7 or 8 or a promoter according to claim 9 comprising a nucleotide sequence substantially as set forth in <400>3 or a nucleotide sequence having at least 25% similarity thereto or a nucleotide sequence capable of hybridising to SEQ ID NO:3 under low stringency conditions.

11. A genetic construct comprising a nucleic acid molecule defining a promoter according to any one of claims 1 to 10.

12. A genetic construct according to claim 11 further comprising a structural or regulatory gene operably linked to said promoter.

13. A method of altering a characteristic of a plant said method comprising introducing a genetic construct according to claim 12 into a cell or group of cells of a plant and wherein said structural or regulatory gene facilitates the altering of said plant characteristic, regenerating a plant or plantlet from said cell or group of cells carrying said genetic construct and growing or subjecting said plant or plantlet to conditions sufficient to induce the promoter in said genetic construct.

14. A method according to claim 13 wherein the altered plant characteristic comprises resistance to a plant pathogen, altered nutritional characteristics, expression of a plantabody, an altered biochemical pathway, altered fertility and/or altered flower colour.

15. A modular promoter, said modular promoter comprising at least one portion which is derived from a promoter which, in its native form, directs expression of a gene associated with ethylene biosynthesis and is inducible by physical stimulation.

16. A modular promoter according to claim 15 wherein the native promoter directs expression of a gene encoding 1-aminocyclopropane-1-carboxylic acid

PCT/AU99/00705

(ACC) synthase.

17. A modular promoter according to any one of claims 15 to 16 wherein the native promoter is selected from the group consisting of:

- (i) a promoter which directs expression of a nucleotide sequence as substantially set forth in <400>1;
- (ii) a promoter which directs expression of a nucleotide sequence which hybridizes under low stringency conditions to <400>1;
- (iii) a promoter which directs expression of a nucleotide sequence having at least about 50% similarity to <400>1;
- (iv) a promoter which directs expression of a nucleotide sequence which encodes an amino acid sequence substantially as set forth in <400>2;
- (v) a promoter which directs expression of a nucleotide sequence which encodes an amino acid sequence which has at least about 50% similarity to <400>2.

18. A modular promoter according to any one of claims 1 to 4 comprising a nucleotide sequence substantially as set forth in <400>3 or a nucleotide sequence having at least 25% similarity thereto or a nucleotide sequence capable of hybridising to <400>3 under low stringency conditions.

19. A transgenic plant comprising a nucleic acid molecule according to any one of claims 1 to 9.

20. A vegetative or reproductive portion of a transgenic plant according to claim 19.

- 69 -

21. A cut or severed flower from a transgenic plant according to claim 19.



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 15/29</b>		A1	(11) International Publication Number: <b>WO 00/12714</b>
			(43) International Publication Date: <b>9 March 2000 (09.03.00)</b>
(21) International Application Number: <b>PCT/AU99/00705</b>		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: <b>31 August 1999 (31.08.99)</b>		Published <i>With international search report.</i>	
(30) Priority Data: <b>PP 5572 31 August 1998 (31.08.98) AU</b>			
(71) Applicant (for all designated States except US): THE UNIVERSITY OF QUEENSLAND [AU/AU]; St Lucia, QLD 4067 (AU).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): BOTELLA MESA, Jose Ramon [ES/AU]; 12 Tad Street, Kenmore, QLD 4069 (AU). CAZZONELLI, Christopher, Ian [AU/AU]; P.O. Box 142, Malanda, QLD 4885 (AU).			
(74) Agents: HUGHES, E., John, L. et al.; Davies Collison Cave, 1 Little Collins Street, Melbourne, VIC 3000 (AU).			
(54) Title: A NOVEL PLANT PROMOTER AND USES THEREFOR			
(57) Abstract			
<p>The present invention relates generally to a novel plant promoter. More particularly, the present invention provides a plant promoter capable of induction by physical and/or environmental stimuli in cells in which the promoter is indigenous and, in the absence of any negative regulatory mechanism, is capable of constitutive expression in cells in which the promoter is non-indigenous. The present invention is further directed to derivatives of the subject promoter including modular forms of the promoter which are, for example, inducible by different physical and environmental stimuli or which are constitutively expressed. The promoter of the present invention has a range of uses including directing expression of genes conferring useful traits on plants.</p>			

PATENT  
Docket No. 229752001300

O I P E JCIS  
JUN 18 2001  
PATENT & TRADEMARK OFFICE

**DECLARATION FOR UTILITY/DESIGN PATENT APPLICATION**

AS A BELOW-NAMED INVENTOR, I HEREBY DECLARE THAT:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled: A NOVEL PLANT PROMOTER AND USES THEREFOR, the specification of which is attached hereto unless the following box is checked:

was filed on February 28, 2001 as United States Application Serial No. or PCT International Application No. 09/763,957 and was amended on (if applicable).

I HEREBY STATE THAT I HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE.

I acknowledge the duty to disclose information which is material to the patentability as defined in 37 C.F.R. § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed:

Application No.	Country	Date of Filing (day/month/year)	Priority Claimed?
PCT/AU99/00705	Australia	8/31/1999	YES
PP5572	Australia	8/31/1998	YES

I hereby claim benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

Application Serial No.	Filing Date

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to

patentability as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Application Serial No.	Filing Date	Status
		<input type="checkbox"/> Patented <input type="checkbox"/> Pending <input type="checkbox"/> Abandoned

I hereby appoint the following attorneys and agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

67-  
Laurie A. Axford (Reg No. 35,053)  
Joseph Barrera (Reg No. 44,522)  
Shantanu Basu (Reg No. 43,318)  
Frank P. Becking (Reg No. 42,309)  
Jonathan Bockman (Reg No. 45,640)  
Barry E. Bretschneider (Reg No. 28,055)  
Nicholas Buffinger (Reg No. 39,124)  
Mark R. Carter (Reg No. 39,131)  
Peng Chen (Reg No. 43,543)  
Thomas Chuang (Reg No. 44,616)  
Cara M. Coburn (Reg No. 46,631)  
Raj S. Davé (Reg No. 42,465)  
Stephen C. Durant (Reg No. 31,506)  
David L. Fehrman (Reg No. 28,600)  
Thomas George (Reg No. 45,740)  
Kenneth R. Glick (Reg No. 28,612)  
Douglas G. Hodder (Reg No. 41,840)  
Charles D. Holland (Reg No. 35,196)  
Wayne Jaeschke, Jr. (Reg No. 38,503)  
Richard D. Jordan (Reg No. 33,519)  
Ararat Kapouytian (Reg No. 40,044)  
Cameron A. King (Reg No. 41,897)  
Rimas T. Lukas (Reg No. 46,451)  
Michael J. Mauriel (Reg No. 44,226)  
Philip A. Morin (Reg No. P-45,926)  
Martin M. Noonan (Reg No. 44,264)  
Catherine M. Polizzi (Reg No. 40,130)  
Debra A. Sheika (Reg No. 33,309)  
Rebecca Shortle (Reg No. 47,083)  
Stanley H. Thompson (Reg No. 45,160)  
E. Thomas Wheelock (Reg No. 28,825)  
Frank Wu (Reg No. 41,386)  
Peter J. Yim (Reg No. 44,417)  
Karen R. Zachow (Reg No. 46,332)

Sanjay S. Bagade (Reg No. 42,280)  
Erwin J. Basinski (Reg No. 34,773)  
Richard R. Batt (Reg No. 43,485)  
Vincent J. Belusko (Reg No. 30,820)  
Kimberly A. Bolin (Reg No. 44,546)  
Tyler S. Brown (Reg No. 36,465)  
A. Randall Camacho (Reg No. 46,595)  
Robert K. Cerpa (Reg No. 39,933)  
Alex Chartove (Reg No. 31,942)  
Thomas E. Ciotti (Reg No. 21,013)  
Matthew M. D'Amore (Reg No. 42,457)  
Peter Davis (Reg No. 36,119)  
Carolyn A. Favorito (Reg No. 39,183)  
Hector Gallegos (Reg No. 40,614)  
Debra J. Glaister (Reg No. 33,888)  
Johnney U. Han (Reg No. 45,565)  
Alan S. Hodes (Reg No. 38,185)  
Peter Hsieh (Reg No. 44,780)  
Madeline I. Johnston (Reg No. 36,174)  
Parisa Jorjani (Reg No. 46,813)  
Richard C. Kim (Reg No. 40,046)  
Kawai Lau (Reg No. 44,461)  
Lisa E. Marks (Reg No. 44,901)  
Gladys H. Monroy (Reg No. 32,430)  
Kate H. Murashige (Reg No. 29,959)  
Irene T. Pleasure (Reg No. 45,506)  
Paul J. Riley (Reg No. 38,596)  
Terri Shieh-Newton (Reg No. 47,081)  
Kevin R. Spivak (Reg No. 43,148)  
Michael R. Ward (Reg No. 38,651)  
Todd W. Wight (Reg No. 45,218)  
David T. Yang (Reg No. 44,415)  
George C. Yu (Reg No. 44,418)

and:

Please direct all communications to:


Barry E. Bretschneider  
Morrison & Foerster LLP  
2000 Pennsylvania Avenue, N.W.  
Washington, D.C. 20006-1888

Please direct all telephone calls to Barry E. Bretschneider at 202-887-1545.


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

30/5/01

100

  
Name: \* Rose Ramon Botella Mesa  
Residence: \* 12 Tad Street, Kenmore, Queensland 4069, Australia RJM  
Citizenship: \* Spanish  
Post Office Address: \* 12 Tad Street, Kenmore, Queensland 4069, Australia

200  
8/6/01

  
Name: \* Christopher Ian Cazzonelli  
Residence: P.O. Box 142, Malanda, Queensland, 4885, Australia RIC  
Citizenship: \* Australian  
Post Office Address: \* P.O. Box 142, Malanda, Queensland, 4885, Australia

Applicant/Patentee: Jose Ramon BOTELLA MESA et al.  
 Serial No./Patent No.: 09/763,957  
 Filed on/Issued: February 28, 2001  
 For: A NOVEL PLANT PROMOTER AND USES THEREFOR

Docket No.: 229752001300

**VERIFIED STATEMENT CLAIMING SMALL ENTITY  
STATUS 37 C.F.R. § 1.9(e) AND § 1.27(d) - NONPROFIT ORGANIZATION**

I hereby declare that I am an official empowered to act on behalf of the non-profit organization identified below:

Name of nonprofit organization: The University of Queensland of St. Lucia

Address of nonprofit organization: Queensland 4067, Australia

Type of nonprofit organization:

University or other institution of higher education  
 Tax exempt under Internal Revenue Service Code (26 U.S.C. §§ 501(a) and 501(c)(3))  
 Nonprofit scientific or educational under a statute of a state of the United States of America  
 Name of state: \*  
 Citation of statute: \*  
 Would qualify as tax exempt under Internal Revenue Service Code (26 U.S.C. §§ 501(a) and 501(c)(3)) if located in the United States of America  
 Would qualify as nonprofit scientific or educational organization under a statute of a state of the United States of America if located in the United States of America  
 Name of state: \*  
 Citation of statute: \*

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 C.F.R. § 1.9(e) for purposes of paying reduced fees to the United States Patent and Trademark Office regarding the invention entitled A NOVEL PLANT PROMOTER AND USES THEREFOR inventor(s) \* described in:

the specification filed herewith.  
 application serial no. 09/763,957, filed February 28, 2001.  
 patent no. \*, issued \*.

I hereby declare that the rights under contract or law have been conveyed to and remain with the nonprofit organization regarding the above identified invention. If the rights held by the nonprofit organization are not exclusive, each individual, concern or organization having rights in the invention must file separate verified statements answering to their status as small entities and that no rights to the invention are held by any person other than the inventor, who would not qualify as an independent inventor under 37 C.F.R. § 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 C.F.R. § 1.9(d) or a non-profit organization under 37 C.F.R. § 1.9(e).

Each person, concern or organization having any rights in the invention is listed below:

no such person, concern or organization exists.  
 each such person, concern or organization is listed below.

NAME	ADDRESS	INDIVIDUAL STATUS
The University of Queensland of St. Lucia	Queensland 4067, Australia	<input type="checkbox"/> Individual <input checked="" type="checkbox"/> Small Business Concern <input checked="" type="checkbox"/> Nonprofit Organization

I acknowledge the duty to file, in this application or patent, notification or any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate (37 C.F.R. § 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING:

TITLE IN ORGANIZATION OF PERSON SIGNING: \*

ADDRESS OF PERSON SIGNING: \*

SIGNATURE: Douglas Porter

DOUGLAS PORTER

Secretary and Registrar

The University of Queensland  
QUEENSLAND 4072

DATE: 27/4/01

PTO/SB/11 (10-92)  
dc-258717